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ONE-SENTENCE SUMMARY: The catalytic activity of multiple Ser/Thr kinases is 16	
regulated through a conserved Cys-based mechanism. 17	
ABSTRACT:  18	
Reactive oxygen species (ROS) are recognized physiological mediators of cellular signaling, 19	
and also play potentially-damaging roles in human diseases. In this study, we demonstrate 20	
that the catalytic activity of the Ser/Thr kinase Aurora A is inhibited by oxidation of a 21	
conserved cysteine residue (Cys 290), which lies adjacent to Thr 288, the activating site of 22	
phosphorylation in the activation segment. We find that ~100 human Ser/Thr kinases possess 23	
a Cys at this position, which is important not only for the regulated activity of Aurora A, but 24	
also fission yeast MAPK-activated kinase (Srk1) and PKA (Pka1). Moreover, the equivalent 25	
cysteine is prognostic for biochemical redox-sensitivity amongst a cohort of human CAMK, 26	
AGC and AGC-like kinases, including PKA, AKT, AMPK, CAMK1, MAPKAP-K2/3, 27	
MELK, SIK1-3 and PLK1/4. We predict that redox modulation of the Cys 290 equivalent 28	
may be an underappreciated regulatory mechanism that is widespread amongst subsets of 29	
eukaryotic protein kinases. Given the key biological roles of these kinases, our work has 30	
important implications for understanding physiological and pathological responses to ROS, 31	




Reactive oxygen species (ROS), the collective term for reactive oxygen-derived radicals 35	
including superoxide and peroxide, were originally regarded as side-products of oxygen 36	
metabolism, but are now recognised as key players in eukaryotic signal transduction [1, 2]. 37	
Endogenous redox signaling in cells is induced in response to growth factors such as EGF [1, 38	
3], and ROS are important regulators of cell migration, differentiation and the proliferative 39	
cell cycle [4-6]. The sulfur atom of Cys residues, the predominant intracellular redox-40	
signaling molecule, can exist in a variety of oxidation states (fig. S1). In ROS-targeted 41	
signaling of proteins, oxidation of a reactive Cys thiolate anion (Cys-S-) results in the 42	
formation of the transient sulfenic acid species (Cys-SOH), which can either undergo further 43	
(irreversible) oxidation to sulfinic (Cys-SO2H) or sulfonic (Cys-SO3H) acid. The sulfenic 44	
species can be stabilised by formation of a disulfide with another Cys or through formation of 45	
a cyclic sulfenamide, as established in the case of the tyrosine phosphatase PTP1B, which can 46	
be recycled to the thiolate in vivo by glutaredoxin or thioredoxin [7-11]. The reduced 47	
glutathione (GSH) pool serves to buffer the cellular environment, with physiological 48	
concentrations ranging from ~1 to 10 mM [12-16]. In the cytosol, glutathione exists as both 49	
oxidized (GSSG) and reduced (GSH) species, and the GSSG/GSH ratio changes as a function 50	
of redox stress [15]. Reversible modification of protein cysteine thiol groups through 51	
disulfide bond formation with GSH is therefore considered to be a defence mechanism, 52	
protecting proteins against proteotoxic stress caused by irreversible oxidation [17].  53	
Protein phosphorylation on Ser/Thr and Tyr residues controls multiple aspects of eukaryotic 54	
life [18]. In order to regulate the precise flow of signaling information, the enzymes that 55	
catalyse the addition and removal of phosphate groups are themselves subject to reversible 56	
regulation. In the case of Ser, Thr and Tyr kinases, this often involves phosphorylation-based 57	
mechanisms in which conserved residues are cyclically phosphorylated and dephosphorylated 58	
to control catalysis. A well-known example is the reversible phosphorylation of Ser/Thr and 59	
Tyr residues in the conformationally-flexible ‘activation segment’, which can either be 60	
liberated or folded-back onto the kinase to inhibit substrate binding and phosphorylation [19]. 61	
The activation segment, also known as the T-loop, is located between the DFG and APE 62	
motifs [20], two highly-characteristic regions found in canonical eukaryotic protein kinases 63	
(ePKs) [21]. In the case of pTyr regulation, redox control of Tyr phosphatases is well-64	
documented [9, 10, 22], providing an extra layer of regulation in addition to reversible 65	
phosphorylation of Tyr kinases such as EGFR [23].  66	
For ePKs, several examples of redox-associated mechanisms have been reported, although the 67	
lack of a catalytic Cys in the active-site means that these mechanisms have been centred on 68	
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other regulatory regions of the kinase domain, most notably modification of conserved Cys 69	
residues in the Gly-rich P-loop. Well-characterized examples of redox-sensitive Tyr kinases 70	
regulated by this mechanism include ABL, SRC, EGFR and FGFR [24-27]. In addition, 71	
several examples of Ser/Thr kinase regulation through redox-active Cys residues exist, 72	
although no overarching evolutionary-based mechanism has been proposed. Examples of 73	
eukaryotic redox-regulated proteins containing Ser/Thr kinase domains include ASK1, 74	
MEKK1, MELK, PKA, PKG, ERK, JNK and p38 MAPK-family members [28-43].  75	
The discovery of chemically-accessible (and redox-sensitive) Cys residues in protein kinases 76	
has created new opportunities for the design of chemical reagents and covalent clinical 77	
compounds to target these residues with impressive specificity [44-48].  However, without a 78	
common set of biochemical reagents and reliable real-time assay conditions, it is currently 79	
challenging to define a common theme or mechanism for redox-based regulation amongst 80	
protein kinases, which are assayed under a variety of different biochemical conditions. 81	
Aurora A is an oncogenic Ser/Thr protein kinase [49], which is subject to multi-level, 82	
reversible regulation in human cells including phosphorylation/dephosphorylation in the 83	
activation segment and allosteric control by accessory factors such as TPX2, TACC3 and 84	
protein phosphatases [50-53]. Aurora A activation controls the G2/M transition [54] and is 85	
also required for centrosome separation and mitotic spindle assembly [55, 56]. Furthermore, 86	
Aurora A-dependent signaling is also implicated in mitochondrial dynamics and metabolism, 87	
which are closely associated with the production of ROS [57].  88	
In this study, we report that the catalytic activity of Aurora A is acutely controlled by a 89	
specific Cys-based oxidation mechanism. DTT-reversible Aurora A oxidation by a variety of 90	
chemical agents occurs through modification of Cys 290, which lies adjacent to Thr 288, the 91	
well-established activating ‘T-loop’ site of phosphorylation. This Cys has been conserved in 92	
all Aurora kinases throughout eukaryotic evolution, and we propose that redox modulation of 93	
the Cys 290-equivalent in distinct eukaryotic kinases might be a dominant, evolutionary-94	
conserved, mechanism, since ~10% of 285,479 protein kinase-related sequences in the non-95	
redundant (NR) sequence database contains a Cys at this position. In addition, we show that 96	
this Cys residue is important for the in vivo activity of PKA and a MAPK-activated kinase in 97	
fission yeast. We then go on to establish that the presence of a Cys residue is prognostic for 98	
redox-sensitivity amongst many human CAMK and AGC-like kinases, but not Tyr kinases, 99	
which lack conserved Cys residues in the activation segment. Important examples of redox-100	
regulated Ser/Thr kinases include PKA, PLK1/4, AKT, SIK, AMPK, MAPKAP-K2/3 and 101	
CAMK1. Overall, our study demonstrates that redox modification of the activation segment 102	
might represent an extra conserved layer of regulation for subsets of eukaryotic protein 103	
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kinases, including a significant proportion of the human kinome. These findings have 104	
implications for understanding physiological and pathological responses to ROS in cells, and 105	
help rationalise numerous lines of experimental evidence demonstrating that reducing agents 106	




Redox regulation of Aurora A 110	
Human Aurora A was purified to homogeneity in the presence or absence of the reductant 111	
DTT, and immunoblotting with a phosphospecific antibody confirmed similar levels of pThr 112	
288 in enzyme preparations, as expected for active, autophosphorylated, Aurora A (fig. S2A). 113	
Regardless of whether it was purified under our standard reducing conditions (+DTT) or not, 114	
Aurora A activity was inhibited by H2O2 in a concentration dependent manner, with ~70 % 115	
inhibition observed at 100 µM H2O2, even when the ratio of enzyme:peroxide was increased 116	
1000-fold (Fig. 1A and fig. S2B-C). Diamide, which also oxidizes exposed cysteine residues 117	
in proteins [58, 59], also inhibited Aurora A activity in a dose-dependent manner (Fig. 1A and 118	
Fig.S2C).  119	
A similar degree of inhibition was observed when much higher concentrations of Aurora A 120	
were exposed to a gradient of peroxide for 16h, in order to mimic chronic physiological 121	
exposure to oxidation (fig. S2B). In contrast, exposure of Aurora A to increasing 122	
concentrations of DTT progressively enhanced catalytic activity, regardless of the purification 123	
protocol employed (compare Fig. 1A and fig. S2C). To further evaluate the redox response of 124	
Aurora A towards a substrate, we employed the physiological Aurora A target TACC3, and 125	
confirmed that phosphorylation at Ser 558 was inhibited in a dose-dependent manner by 126	
H2O2, similar to the Aurora A inhibitor MLN8237 (Fig. 1B). In marked contrast, DTT 127	
increased phosphotransferase activity towards TACC3 (Fig. 1B). A prerequisite for Aurora A 128	
activation is autophosphorylation on Thr 288 in the activation loop [60, 61], which is 129	
generated in this experiment during bacterial maturation prior to purification. Importantly Thr 130	
288 was highly phosphorylated under all of the tested conditions, regardless of the presence 131	
of DTT and/or H2O2, suggesting that oxidative inhibition of Aurora A was not a result of 132	
peroxide-induced dephosphorylation at this regulatory site (Fig. 1B). Next, we sought to 133	
establish if H2O2 exposure led to irreversible inhibition of Aurora A. We quantified the real-134	
time phosphorylation of a substrate peptide by Aurora A that had been previously exposed to 135	
H2O2. When H2O2 was included in the reaction, only ~15 % of the peptide substrate was 136	
phosphorylated after 25 mins, compared to ~60% in its absence (Fig. 1C, left panel). 137	
However, supplementing the reaction with DTT restored H2O2 –inhibited Aurora A activity, 138	
resulting in an immediate increase in the rate of substrate phosphorylation comparable to a 139	
control maintained in an oxidized (inhibited) state (Fig. 1C, left panel). Similarly, the activity 140	
of Aurora A purified in the presence of DTT, then inhibited by H2O2 was also rescued in real-141	
time by the addition of DTT (fig. S2D). In contrast, DTT was ineffective at reactivating 142	
Aurora A inhibited by MLN8237 (Fig. 1C, right panel). These findings indicate that the 143	
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catalytic activity of Aurora A is reversibly inhibited by oxidation. Importantly, the inclusion 144	
of H2O2 did not affect the amount of Aurora phosphorylated on Thr 288, although we noted 145	
that H2O2-treatment did cause a slight increase in the electrophoretic mobility of Aurora A 146	
(Fig. 1D, asterisk). This mobility shift was abolished by DTT, consistent with the presence of 147	
a reversibly oxidized Cys residue (or residues) in Aurora A [62, 63]. 148	
To rule out ‘non-specific’ kinase inactivation as a result of oxidative protein unfolding or 149	
multi-site oxidation, we performed thermal stability measurements for Aurora A incubated in 150	
the presence of H2O2. The unfolding profile obtained for Aurora A was unaltered by inclusion 151	
of H2O2, DTT or reduced glutathione (GSH), with Tm values of ~40°C observed under test 152	
conditions (fig. S3A). In order to evaluate the consequences of Aurora A oxidation on the 153	
ability to bind Mg-ATP, we measured the rate of phosphate incorporation into the peptide 154	
substrate in the presence of different H2O2 concentrations. Michaelis-Menten kinetic analysis 155	
revealed that H2O2 treatment significantly reduced the catalytic constant, Kcat, of Aurora A, 156	
without affecting the affinity for ATP at the highest concentrations tested (inferred from 157	
KM[ATP] values) (fig. S3B). Consistent with a lack of direct effects on the nucleotide-binding 158	
site, DSF analysis demonstrated that almost identical ∆Tm values were calculated after 159	
binding of ATP or the inhibitor MLN8237 in the presence of H2O2, DTT or GSH (fig. S3C). 160	
Together, these data indicate that oxidation inhibits the ability of Aurora A to drive substrate 161	
(peptide and protein) phosphorylation without affecting the affinity for ATP or the thermal 162	
stability (unfolding) profile of the enzyme.  163	
Aurora A autoactivation is stimulated by DTT and inhibited by H2O2 164	
As an additional measure of the ability of H2O2 to inhibit Aurora A activity we investigated 165	
the rate of autophosphorylation in Aurora A generated by bacterial co-expression with lambda 166	
phosphatase (λPP), which removes all activating phosphate from Thr 288, then subsequently 167	
re-purified it to remove residual phosphatase. Accumulation of pThr 288 was then assessed 168	
by immunoblotting following the addition of Mg-ATP in the presence and absence of the 169	
known allosteric activator TPX2. Under standard assay conditions, Aurora A 170	
autophosphorylation was extremely slow, and only trace amounts of pThr 288 Aurora A were 171	
detected after 60 mins (Fig. 1E). As predicted, inclusion of DTT and/or TPX2 markedly 172	
increased the rate of Aurora A autophosphorylation, whereas no phosphorylation was 173	
detected in the presence of H2O2, even in the presence of TPX2 (Fig. 1E). These data confirm 174	
that, although peroxide treatment does not lead to loss of Thr 288 phosphorylation in 175	
phosphorylated Aurora A, reducing conditions are required to stimulate efficient 176	
autoactivation of the unphosphorylated ‘ground-state’ form of the enzyme in vitro.  177	
Identification of Cys 290 as the site of Aurora A redox regulation 178	
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The observation that Aurora A is reversibly inhibited by H2O2 in vitro and that this inhibition 179	
is associated with a reversible mobility shift (Fig. 1D) raised the possibility that ROS may 180	
directly regulate Aurora A activity in vivo. The reversible oxidative modification of signaling 181	
proteins is associated with oxidation of the sulfur-containing amino acids cysteine and 182	
methionine, with the initial oxidation of a specific cysteine-thiol generating a reversible 183	
sulfenyl (SOH) derivative (Fig. S1) [64]. To investigate the presence of Cys-SOH in Aurora 184	
A, we exploited an antibody that detects SOHs that have been selectively and covalently 185	
derivatized with dimedone [5, 6, 65]. Sulfenylated Aurora A was readily detected (Fig. 2A), 186	
with the signal increasing progressively after exposure to increasing concentrations of H2O2 187	
(Fig. 2B). Incubation of Aurora A with DTT markedly-reduced dimedone-labelling (Fig. 2B), 188	
consistent with the regeneration of Cys thiols, which are refractory to dimedone adduct 189	
formation. Importantly, no labelling of the protein was detected in the absence of dimedone, 190	
confirming antibody specificity (Fig. 2A). 191	
To identify potential redox-sensitive Aurora A residues, we employed the bioinformatics tool 192	
Cy-preds [66], which highlighted the surface residue Cys 290 as a potential target for 193	
oxidative modification of the seven human Aurora A Cys residues. Cys 290 is highly 194	
conserved, and lies within the canonical activation segment, in very close proximity to the 195	
regulatory Thr 288 side-chain. Interestingly, the equivalent Cys in PKA has previously been 196	
analysed in terms of redox regulation, with a role for Cys 200 established in vitro [59, 67]. To 197	
assess whether regulatory oxidative modification of Aurora A could be specifically assigned 198	
to Cys 290, we generated Aurora A containing a Cys to Ala substitution at this position (fig. 199	
S4A). When compared to WT Aurora A, incorporation of the C290A mutation had no effect 200	
on protein thermostability (Tm ~40°C, fig. S4B) measured by DSF [68, 69] or ∆Tm values 201	
induced by ATP or inhibitor (MLN8237) binding (fig. S4C). Furthermore, KM[ATP] values 202	
obtained in peptide-based kinase assays were virtually identical for both kinases, although the 203	
C290A mutant exhibited decreased activity (~50 % of WT, fig. S4D). This latter observation 204	
is consistent with previous analysis of a C290A Aurora A mutation [70], and emphasizes the 205	
potential importance of this residue as a regulatory hot-spot within the activation loop.  206	
We next tested whether Cys 290 might be prone to oxidation by comparing the H2O2-induced 207	
sulfenylation of WT and C290A Aurora A. Immunoblotting revealed dimedone labelling was 208	
greatly diminished in C290A Aurora A compared to WT, indicative of a reduction in the 209	
number of Cys residues undergoing sulfenylation (Fig. 2C). Critically, mutation of Cys 290 210	
protected Aurora A from inhibition by H2O2 (Fig. 2D). This manifested as an increase in the 211	
half-maximal inhibitory concentration (IC50) of H2O2 from ~35 µM for WT Aurora A to ~10 212	
mM for C290A Aurora A. Concomitantly, C290A mutation abolished DTT dependent 213	
activation of Aurora A (Fig. 2E). Finally, we investigated C290A Aurora A-dependent 214	
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phosphorylation of TACC3, observing that catalytic activity towards this physiological 215	
substrate was unaffected by the presence of either reducing or oxidizing agents (fig. S4E). 216	
Together these results confirm that Cys 290 plays a central role in a new regulatory 217	
mechanism that underpins Aurora A kinase activity in vitro, and suggests that this may be a 218	
direct result of a switch between oxidized ‘inactive’ and reduced ‘active’ catalytic states.  219	
The reduced C290A phosphotransferase activity in comparison to WT Aurora A (fig. S4) 220	
indicated that an Ala substitution was not optimal in terms of catalysis. Based on its similar 221	
size, structure and hydrophilic properties, Ser is potentially a better-suited (non-redox-222	
sensitive) mimic of this Cys residue. However, introduction of a Ser (or Asp) residue at the 223	
Cys 290 position generated Aurora A that was devoid of Thr288 phosphorylation (fig. S5A) 224	
despite no detectable changes in protein stability (as judged by Tm values, fig. S5B) or binding 225	
to ATP or MLN8237 (fig. S5C), confirming an inability of the kinase to autophosphorylate 226	
and autoactivate. Consistently, both C290S and C290D mutants were also completely 227	
catalytically inactive when evaluated real-time (fig. S5D). These observations reveal the 228	
extraordinary sensitivity of Aurora A to modest structural perturbations at the Cys 290 229	
position, and further establishes the potential regulatory role of this conserved site in the 230	
activation segment. In agreement with published findings, PKA activity was also inhibited in 231	
a concentration dependent manner by H2O2 [59, 67, 71] whereas DTT modestly stimulated 232	
kinase activity (Fig. 2F). Importantly, and in agreement with previous findings [59], the 233	
inhibitory effect of H2O2 was completely abrogated in the site-specific cysteine mutant PKA 234	
C200A (Fig. 2G). Moreover, inhibition of PKA by H2O2 was due to the reversible oxidation 235	
of a sulfhydryl residue, since activity could be fully restored in real-time by DTT exposure 236	
(Fig. 2F).  237	
TPX2 protects Aurora A from inactivating oxidation 238	
In addition to autophosphorylation of Thr 288 in the activation loop, which lies adjacent to 239	
Cys 290 (Fig. 2H), Aurora A can be activated allosterically by interaction(s) with the spindle 240	
assembly factor TPX2 [50, 72-75]. Given that binding to TPX2 and phosphorylation of the 241	
activation loop are complementary mechanisms for Aurora A activation, we investigated 242	
redox regulation of Aurora A in the context of TPX2. First we considered the effect of redox 243	
state on the interaction between Aurora A and TPX2. Aurora A was exposed to increasing 244	
concentrations of H2O2 or DTT and then evaluated for its ability to interact with GST-tagged 245	
TPX2. GST pull-down assays revealed that Aurora A remained associated with GST-TPX2 246	
even at the highest concentrations of H2O2 and DTT employed (fig. S6A). Thus, the redox 247	
state of Aurora A had no detectable effect on binding to TPX2 in vitro. Next, we examined 248	
inhibition of Aurora A by H2O2 in the presence of TPX2. The phosphorylated activation loop 249	
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of Aurora A has recently been shown to adopt a range of conformations in solution, only 250	
becoming highly ordered in a stable ‘DFG-in’ conformation upon TPX2 binding [75]. 251	
Furthermore, both ‘inactive’ unphosphorylated and ‘active’ phosphorylated Aurora A adopt 252	
similarly well-defined structures upon TPX2 binding, resulting in an increase in kinase 253	
activity [51, 75]. We found that TPX2 increased the resistance of Aurora A to inhibition by 254	
H2O2, increasing the IC50 [H2O2] value to > 1 mM (Fig. 2I). Importantly, the modest 255	
inhibitory effect of H2O2 on the TPX2-Aurora A complex could be completely reversed in 256	
real-time upon addition of DTT (Fig. 2J). Allosteric activation of Aurora A by TPX2 is 257	
therefore sufficient to overcome kinase inactivation by oxidation under these conditions. It is 258	
possible that oxidation of Aurora A at Cys 290 alters the structural dynamics of the activation 259	
loop and stabilizes a less active subpopulation, with activity being recapitulated following 260	
binding to, and structural reorganization by, TPX2. This is supported by the observation that 261	
C290A Aurora A, which displays lower kinase activity compared to the WT protein, is also 262	
strongly activated by TPX2 binding, but unlike WT Aurora A remains resistant to inhibition 263	
by H2O2 when TPX2-bound (fig. S6B, C). Importantly activities of WT and C290A Aurora A 264	
were unaffected by GST (fig. S6C). Furthermore, C290S (but not C290D) Aurora A, which 265	
lacks kinase activity (and phosphorylation at Thr288) when evaluated in isolation, was 266	
partially activated in the presence of TPX2 (but not DTT) in our peptide assay, and displayed 267	
clear phosphotransferase activity towards TACC3 (fig. S6D, and E).   268	
Aurora A can also be activated by glutathionylation on Cys290 269	
Sulfenylated cysteines are susceptible to further, irreversible, oxidation. In vivo, reversibility 270	
can be ensured by formation of a disulphide with a cysteine in glutathione or another protein 271	
(fig. S1). We therefore investigated the influence of reduced (GSH) or oxidized (GSSG) 272	
glutathione alongside a panel of other redox-active compounds on Aurora A activity. Aurora 273	
A activation by the reducing agents DTT, tris(2-carboxyethyl)phosphine (TCEP) and 2-274	
mercaptoethanol (2-ME) was confirmed by enhanced rates of peptide substrate 275	
phosphorylation compared to control assays (Fig. 3A). Notably, the inclusion of GSH (or 276	
GSSG) in the assay also induced a measurable increase in activity (Fig. 3A). This increased 277	
Aurora A activity is in contrast to PKA, which is reported to be inhibited by GSH [59]. 278	
Consistently, C290A Aurora A was more resistant to activation by these reducing agents (Fig. 279	
3B). Importantly, and in contrast to WT Aurora A, which demonstrated concentration-280	
dependent activation by GSH, C290A Aurora A only exhibited modest increases (~1.5-fold) 281	
in activity at the highest tested GSH concentrations (Fig. 3C). Next we investigated whether 282	
modulation of Aurora A activity was a consequence of mixed disulfide formation between 283	
Cys 290 and glutathione. To probe for glutathionylation, we employed an antibody that 284	
specifically reacts to protein-glutathione complexes (Fig. 3D).  PKA was included as a 285	
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positive control as it has previously been shown to be glutathionylated [59]. Glutathionylation 286	
was readily detected for WT Aurora A incubated with GSSG, but not for the C290A mutant, 287	
suggesting that changes in Aurora A activity were a direct result of glutathionylation of this 288	
cysteine (Fig. 3D)(fig. S7A). However, despite stimulating Aurora A activity, addition of 289	
GSH alone was insufficient to restore the activity of oxidized Aurora A (Fig. 3E), which 290	
required reduction by DTT (fig. S7B) or enzymatic deglutathionylation by glutaredoxin-1 291	
(GRX) (fig. S7C) to restore Aurora A catalytic activity. The AGC kinase AKT has previously 292	
shown to be regulated by glutathione-dependent mechanisms [36]. To confirm AKT 293	
glutathionylation using real-time assay, PDK1-phosphorylated S473D AKT was incubated 294	
with GSH in the presence and absence of H2O2. Similar to Aurora A, AKT was covalently 295	
modified by glutathione (Fig. 3F). The catalytic activity of AKT was enhanced several 296	
hundred-fold by GSH exposure in the absence of H2O2 (fig. S7D). Furthermore, the activity 297	
of AKT was rapidly inhibited by oxidation, and could be restored by the addition of DTT. 298	
The subsequent addition of GSH did not rescue activity (Fig. 3G), as demonstrated for Aurora 299	
A. 300	
Oxidative stresses inhibits Aurora A substrate phosphorylation in human cells 301	
To validate our in vitro findings, we next investigated whether Aurora A activity is redox-302	
regulated in human cells, employing the endogenous substrate TACC3 phosphorylation as an 303	
intracellular read-out for Aurora A activity [76, 77]. HeLa cells were initially synchronized 304	
with nocodazole, and then exposed to H2O2 or DTT for 30 mins. Western blotting revealed a 305	
dose-dependent decrease in TACC3 phosphorylation at Ser 558 in cells treated with H2O2 306	
compared both to control cells, and those treated with DTT (Fig. 4A-B). As expected, cells 307	
incubated with the Aurora A inhibitor MLN8237 demonstrated complete loss of TACC3 308	
phosphorylation (Fig. 4A), whereas nocodazole exposure alone, which has recently been 309	
shown to enhance the oxidation of Cys residues [5], did not lead to net Aurora A inhibition.  310	
We next determined the effects of the cell-permeable oxidant diamide [58]. Strikingly, the 311	
extent of TACC3 phosphorylation was inversely proportional to the diamide concentration, 312	
analogous to observations with H2O2 (Fig. 4C). Menadione is a quinone oxidant that 313	
stimulates rapid generation of cellular ROS through redox-cycling [78]. Menadione exposure 314	
also caused a concentration-dependent inhibition of TACC3 phosphorylation (Fig. 4D). 315	
Aurora A protein levels were not affected by H2O2, diamide or menadione eliminating the 316	
possibility that degradation was the cause of reduced TACC3 phosphorylation. (Fig. 4A-D). 317	
Finally, we investigated the effect of chronic oxidative stress on Aurora A activity. Glucose 318	
oxidase (GO) was added to nocodazole-containing culture medium at a non-toxic 319	
concentration (2 U/ml) to facilitate the generation of peroxide. At this level of enzyme 320	
activity, GO is reported to generate intracellular steady-state levels of H2O2 of 1-2 µM [79-321	
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81]. As shown in Fig. 4E, GO also resulted in a time-dependent decrease in TACC3 322	
phosphorylation. To evaluate the physiological relevance of Aurora A redox regulation as a 323	
signaling mechanism, we also investigated the reversibility of inactivation. Cells were 324	
exposed to H2O2 prior to incubation with DTT or the cellular antioxidants GSH and N-acetyl-325	
L-cysteine (NAC). Under these conditions, TACC3 phosphorylation was restored to basal 326	
levels by both GSH and NAC, presumably due to ROS scavenging (Fig. 4F). However, in the 327	
presence of H2O2, DTT was unable to rescue TACC3 phosphorylation.  328	
Next, we analyzed Cys 290-based regulation in Aurora A. HeLa cells were transiently 329	
cotransfected with GFP-tagged TACC3 in the presence or absence of either WT or C290A 330	
Myc-tagged Aurora A, and synchronised with nocodazole in order to activate Aurora A. GFP-331	
tagged TACC3 became phosphorylated at Ser 558 by endogenous Aurora A following 332	
nocodazole treatment, with a concomitant decrease of phosphorylation at this site in the 333	
presence of diamide (Fig. 4G). Transient overexpression of either WT or C290A Myc-tagged 334	
Aurora A also led to an increase in GFP-TACC3 phosphorylation at Ser 558. Importantly, we 335	
detected a diamide-induced, dose-dependent decrease in GFP-TACC3 phosphorylation co-336	
transfected with WT Aurora A, consistent with inhibition of Aurora A by oxidation. In 337	
contrast, the inhibitory effect of diamide on GFP-TACC3 phosphorylation was blunted in 338	
cells expressing C290A Aurora A (Fig. 4G). Taken together, these data suggest that C290 in 339	
Aurora A is important for inhibition of Aurora A kinase activity in response to oxidants in 340	
cells. 341	
Cys residues are evolutionary conserved in a variety of ePK activation segments  342	
Cys is the second least-common amino acid in vertebrate proteomes [82], and although 343	
>200,000 Cys residues are present in the human proteome, they are often conserved in redox 344	
‘hot-spots’ [83]. Reactive Cys side chains, especially those lying on surface-exposed regions 345	
of proteins [66], are often susceptible to redox modification (fig. S1). To investigate the 346	
potential generality of Cys-based redox mechanism in protein kinases that possess an 347	
activation segment, we analyzed >250,000 protein kinase related sequences, confirming that 348	
~11.5% of ePKs found across the kingdoms of life possess the Cys 290 equivalent of Aurora 349	
A (Fig. 5A). This number reduced to 1.4% of all ePKs when the co-conservation of Cys 350	
residues at the DFG +2 and ‘T-loop +2’ positions, which individually are the most prevalent 351	
in these kinases, were considered side-by-side (Fig. 5A, bottom). Strikingly, the Cys 290-352	
equivalent residue (see Table 1) was very strongly associated with two of the seven human 353	
kinase groups: the AGC kinases and the CAMKs (Fig. 5B), and this pattern was also 354	
observed in kinomes from all the kingdoms of life, including model genetic organisms such 355	
as fungi (fig. S8A-E). Intriguingly, Cys residues are encoded locally in eukaryotic kinomes at 356	
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every possible position within the conserved activation segment (fig. S8F and Table 2). 357	
However, analysis of all canonical human kinases and pseudokinases demonstrated that most 358	
of the Cys-containing kinases belong to families encoding Ser/Thr kinases, notably stress-359	
activated protein kinase kinases such as MAPKAP-K2/3, MKK3, MKK4, MKK6 and MKK7 360	
and Cys-rich pseudokinases such as Tribbles 1-3 [69], all of which possess a conserved Cys at 361	
the DFG + 4 position [84]. 362	
The conserved redox-sensitive cysteine is important for the in vivo activities of the 363	
fission yeast PKA, Pka1, and the MAPK-activated kinase, Srk1 364	
Having established that C290 is important for the activity and redox-sensitivity of human 365	
Aurora kinase, we investigated whether the equivalent Cys was important for the in vivo 366	
activity of well-characterised examples of the AGC and CAMK groups in the fission yeast 367	
Schizosaccharomyces pombe, by studying the single PKA catalytic subunit (Pka1) and the 368	
MAPK activated kinase, Srk1, which is a homologue of human MAPKAP-K2[85, 86]. 369	
Initially, we examined whether C358, equivalent to C200 in human PKA (Fig. 5C & 6A), was 370	
important for the activity of the single catalytic subunit of PKA, termed Pka1, by ectopically 371	
expressing wild-type Pka1 or Pka1 in which C358 was substituted with serine (C358S) or 372	
alanine (C358A) in Dpka1 mutant cells. Immunoblotting with antibodies that recognise 373	
cellular phosphorylated PKA substrates [87] detected fewer bands in pka1 mutant cells than 374	
wild-type (pka1+) cells, confirming that these bands represented substrates of Pka1. Notably, 375	
high-level ectopic expression of wild-type Pka1 restored the missing phosphorylated Pka1 376	
substrate signals, increasing their intensity to wild-type levels, and confirming that Pka1 377	
substrate phosphorylation was restored. In contrast, despite similar expression (Fig. 6B) 378	
Pka1C358S and Pka1C358A, only partially restored Pka1 activity (Fig. 6B). Pka1 has a number of 379	
well-established roles in regulating S. pombe growth and survival under stress conditions. For 380	
example, Dpka1 mutant cells are unable to adapt and grow in high salt conditions [88] (Fig. 381	
6C). We therefore examined whether C358 in Pka1 was important for adaptation to high salt 382	
by comparing the growth of Dpka1 mutant cells expressing wild-type Pka1, Pka1C358S or 383	
Pka1C358A on plates containing 1M KCl. Consistent with C358 playing an important role in 384	
Pka1 activity, neither Pka1C358S and Pka1C358A was able to restore growth to the same extent as 385	
wild-type Pka1 (Fig. 6C).  386	
Next we examined whether the equivalent conserved cysteine was important for the activity 387	
of the MAPK-activated kinase Srk1. Srk1 expression delays entry to mitosis by 388	
phosphorylating the dual-specificity phosphatase CDC25 [89]. Accordingly, in cells 389	
ectopically over-expressing Srk1 from a multi-copy plasmid CDC25 is excluded from the 390	
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nucleus, causing a G2 delay that results in some substantially elongated cells (Fig. 6D), and 391	
increases the mean length of cells at mitosis (Fig. 6D). In contrast, despite similar expression 392	
levels (Fig. 6E), ectopic expression of Srk1C324S or Srk1C324A produced a much more modest 393	
increase in cell length (Fig. 6D) and failed to block nuclear localisation of CDC25 (Fig. 6F). 394	
This permits us to conclude that C324 in Srk1 is important for the in vivo activity of Srk1 in 395	
delaying mitotic entry by phosphorylating CDC25 [89]. Together these data establish that the 396	
T-loop +2 Cys plays an important role in the in vivo activity of both these kinases, raising the 397	
possibility that redox modification of this cysteine may regulate the roles of these kinases in 398	
controlling cell division and stress resistance.   399	
Analysis of human MAPKAP-K2 and Polo-like kinases.  400	
To further investigate the importance of the T-loop +2 Cys in redox regulation, we analysed a 401	
variety of T-loop + 2 Cys-containing kinases (Fig. 5C), beginning with MAPKAP-K2, PLK1, 402	
and PLK4, which were assayed using the redox microfluidic kinase assay developed for 403	
Aurora A, but individually modified to include kinase-specific peptide substrates (Table 2). 404	
To aid comparison, the activity of each kinase was measured in the presence or absence of 405	
increasing concentrations of H2O2 or DTT and the reversibility of redox-dependent 406	
modulation measured using the H2O2 and DTT ‘rescue’ procedure developed for Aurora A.  407	
Recombinant bacterially-expressed GST-tagged MAPKAP-K2 was activated by DTT, and 408	
inhibited by peroxide, but was reactivated by subsequent exposure to DTT (Fig. 7A). To 409	
evaluate this effect in MAPKAP-K2 purified from human cells, we generated 3C protease-410	
cleavable MYC-tagged constructs of WT and C244A MAPKAP-K2 and purified them from 411	
HEK 293T cells (Fig. 7B). Following immunoprecipitation, bound proteins were eluted using 412	
3C protease, and then assayed in real-time the presence of DTT or diamide. Strikingly, the 413	
inhibitory effect of diamide on WT MAPKAP-K2 activity was reduced in the C244A 414	
MAPKAP-K2 mutant (Fig. 7C), confirming this cysteine is required for full oxidative 415	
inhibition of this kinase.  416	
The Aurora kinases and Polo-like kinases (PLKs) both perform complementary mitotic roles 417	
[90]. The PLK family are stringently regulated multifaceted modulators of mitosis and 418	
cytokinesis [91], and the close regulatory relationship between  PLK1 and Aurora A in 419	
mitosis [54, 92] led us to investigate potential redox regulation for PLK1 and PLK4. [93]. We 420	
demonstrated dose-dependent activation and inhibition of bacterially-expressed truncated 421	
PLK1 by DTT and H2O2 respectively (Fig. 7D), and inhibitory oxidation was completely 422	
reversed in real-time by subsequent exposure to DTT (Fig. 7E). However, mutation of the T-423	
loop +2 Cys residue of truncated PLK1 (amino acids 1-361) purified from E.coli resulted in a 424	
kinase that was catalytically inactive, which prohibited further analysis. We next 425	
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immunoprecipitated full-length PLK1 from human cells (Fig. 7F) and compared WT and 426	
C212A PLK1 using the same substrate peptide (Fig. 7G). Consistently, full length PLK1 was 427	
inhibited by both diamide and the inhibitor BI2536 (Fig. 7G). Interestingly, not only was full-428	
length C212A PLK1 catalytically active, but peptide phosphorylation was preserved under 429	
experimental conditions that led to the complete inactivation of WT PLK1 (Fig. 7G).  430	
Additionally, we evaluated the related Ser/Thr kinase PLK4, a ‘master’ centrosomal kinase 431	
[94, 95], which possesses a conserved Cys residue (Cys 172), +2 residues from the T-loop 432	
autophosphorylation site (Thr 170). Consistently, PLK4 was reversibly inhibited by H2O2 and 433	
activity was both rescued and stimulated under reducing conditions (Fig. 7H). Moreover, 434	
C172A PLK4 was refractory to inhibition by oxidation, confirming the role of this Cys 435	
residue as a central regulator of catlalytic activity (Fig. 7I). Supporting the evolutionary 436	
relevance of these novel findings, analysis of homologous kinases demonstrated that the Cys 437	
290-equivalent was conserved across all known eukaryotic Aurora, PKA and Polo-like 438	
kinases (fig. S8A-E) 439	
The presence of a Cys at residue DFG + 2 converts Aurora A into an enzyme that 440	
requires DTT for activity.  441	
To help understand the mechanism of redox regulation in Aurora A, we investigated the DFG 442	
+2 amino acid in Aurora A, which is a Ser or Ala in all multicellular vertebrates (Fig. 8A), 443	
but which is a Cys in many apicomplexan and fungal species. We first analysed purified 444	
Aurora A DFG +2 mutants side-by-side (fig. S10A). The presence of an Ala residue at 445	
position 278 did not change thermal stability (fig. S10B, C) or alter the redox-sensitive 446	
catalytic output of Aurora A (Fig. 7B, left and middle), whereas introduction of a Cys residue 447	
had a dramatic effect, with S278C exhibiting a DTm of 5°C and an absolute requirement for 448	
DTT in order to drive catalytic activity (Fig. 8B, right and Fig. 8C and 8D). Like WT Aurora 449	
A, S278A was still reversibly inhibited by peroxide and activated by DTT, in contrast to 450	
S278C, which was inactive until DTT was spiked into the assay (Fig. 8E, right panel). 451	
Immunoblotting confirmed that S278C contained lower levels of Thr288 autophosphorylation 452	
after purification (fig. S10D), which likely contributes to lower activity, but which cannot 453	
explain the dramatic, and instantaneous, effect of DTT on catalysis. We predicted that the 454	
obligate requirement for DTT to activate S278C Aurora A was due to an inhibitory 455	
intermolecular disulfide bond forming between Cys 290 and the newly introduced Cys 278, in 456	
a manner analogous to other DFG 2+ cysteine containing kinases that also possess cysteines 457	
at the T-loop +2 position, such as AKT and MELK (see below). This hypothesis was 458	
confirmed by inspection of peptides derived from S278C Aurora A by liquid 459	
chromatography-tandem mass spectrometry (LC-MS/MS), which revealed the presence of a 460	
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DTT-reversible intramolecular disulfide bond formed between Cys 278 and Cys 290 that was 461	
absent in WT Aurora A (Fig. 8F). 462	
AKT and MELK require the presence of a reducing agent for catalysis. 463	
Under identical assay conditions to those described above, we next confirmed that the 464	
inclusion of DTT in the buffer enhances AKT catalytic activity several hundred-fold (Fig. 465	
8G). In contrast, oxidation completely prevents AKT-dependent substrate peptide 466	
phosphorylation, although activity can be restored, or even enhanced, by subsequent DTT 467	
exposure, similar to our findings with S278C Aurora A. Consistently, both of these proteins 468	
contain spatially-related Cys residues in the activation segment (Fig. 5A and Fig. 8A). 469	
Maternal embryonic leucine zipper kinase (MELK) is a member of the CAMK kinase 470	
grouping, and is closely related to the AMPK-related kinases [96, 97]. Redox regulation of 471	
MELK has previously been reported, although precise regulatory mechanisms remains 472	
unclear [98]. Interestingly, the activation segment of MELK contains two consecutive Cys 473	
residues (Fig. 5C), one of which might form an intermolecular disulfide bond with a Cys 474	
supplied by the DFG +2 Cys, as previously described for an inhibited oxidized state of 475	
AKT[36, 99]. MELK exhibited very low activity in the absence of DTT, with activity 476	
increasing several hundred-fold after inclusion of DTT in the assay (Fig. 8H). H2O2 inhibited 477	
MELK activity in a dose-dependent manner, and DTT-dependent activation was so 478	
pronounced that MELK activity rapidly surpassed control levels when DTT was used to 479	
‘rescue’ H2O2-inhibition (Fig. 8I). Individual C168A and C169A point mutation blocked 480	
DTT-dependent MELK activation, but neither mutation in isolation completely abrogated 481	
MELK redox-sensitivity, particlulary oxidation by peroxide (Fig. 8I). However, combined 482	
mutation (C168A/C169A MELK) abolished DTT-dependent activation, and these Cys 483	
mutations diminished dimedone adduct formation, especially under control conditions in the 484	
absence of peroxide (fig. S9B), extending previous findings [98].  485	
Evaluation of redox regulation in a Cys-containing CAMK and AGC kinase panel  486	
To establish generality for a Cys-based mechanism of Ser/Thr kinase regulation, we increased 487	
the scope of our analysis to incorporate a panel of protein kinases containing an evolutionary-488	
conserved Cys residue in the T-loop +2 position of the activation segment (Fig. 5C). All 489	
enzymes were purified (or supplied) in the presence of 1 mM DTT, and assayed in real-time 490	
using peptide substrates. Catalytic activity was quantified in the presence of additional DTT, 491	
H2O2 or H2O2 followed by DTT. Remarkably, the majority of kinases tested displayed redox-492	
dependent regulation. Redox analysis of MAPKAP-K3 demonstrated potent inhibition of 493	
enzyme by peroxide (Fig. 9A). Consistent, with our observations with GST-MAPKAP-K2 494	
(Fig. 7A), DTT also activated and restored activity to peroxide-treated MAPKAP-K3 (Fig. 495	
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9A). The removal of the GST tag in the MAPKAP-K3 preparation eliminating any possibility 496	
that the redox regulation of kinase activity was mediated by the affinity tag (Fig. 7A).  497	
The 5'-AMP-activated protein kinase holoenzyme complex (AMPK, comprised of α1, β2 and 498	
γ1 subunits) is a member of the CAMK family and was also inhibited by H2O2 in a DTT-499	
reversible manner (Fig. 9B). These findings support a growing body of evidence that ROS 500	
participate in the regulation of AKT and AMPK activity, although the precise mechanisms 501	
remain controversial. Interestingly, direct activation of AMPKα catalytic subunits in the 502	
presence of H2O2 has previously been described [100], whereas inhibition of AMPKα activity 503	
through Cys130/174 oxidation has also been reported [34]. Cys174 in AMPKα is analogous 504	
to Cys 290 of Aurora A, and is situated two amino acids C-terminal to the Thr172 505	
phosphorylation site, the critical positive modulator of AMPK activity by ‘upstream’ kinases. 506	
The salt-inducible kinases (SIK1-3) are members of the AMPK-related family of CAMKs 507	
[101] and all contain a T-loop + 2 Cys residue. Consistently, purified SIK1-3 were all 508	
reversibly inhibited after H2O2 exposure (Fig. 9C-E). Interestingly, H2O2 was also weakly- 509	
and reversibly inhibitory towards phosphorylase kinase, PHKγ, a member of the CAMK 510	
group (fig. S11A).  511	
Protein Kinase G (PKG) belongs to the AGC group of kinases, although its mechanism of 512	
regulation is distinct from that of closely related PKA and PKC isozymes. However, and in 513	
contrast to other T-loop Cys-containing AGC kinases tested (including PKA and AKT), there 514	
was no evidence for oxidative inhibition of the PKG1 splice variants PKG1-1 or PKG1-2, 515	
when they were assayed in either the absence, or presence, of cGMP (fig. S11B-E), which is 516	
consistent with recent findings [38]. In contrast, oxidative modification of PKG1-1 (but not 517	
PKG1-2) was previously suggested to result in activation of the kinase in a cGMP-518	
independent manner [31], but we were unable to detect such an effect using our assay system 519	
(fig. S11). 520	
CAMK1 has been reported to be inhibited by glutathionylation of Cys179 in the activation 521	
segment [102]. Consistently, we found that oxidation was sufficient to inactivate two 522	
isoforms of CAMK1, CAMK1A and CAMK1D, both of which were assayed in an identical 523	
fashion (Fig. 9F-G). Inactivation is potentially as a consequence of Cys179 oxidation, and 524	
likely independent of the GST affinity tag, since it was proteolytically excised in the 525	
CAMK1A sample, but still present in CAMK1D. Consistently, DTT exposure reversed H2O2-526	
dependent inhibition of both CAMK1 isoforms (Fig. 9F-G). The related kinase CAMK2 lacks 527	
an activation segment T-loop + 2 Cys residue, but redox-regulation of dual-Met residues has 528	
been reported to promote CAMK2 activation by stabilizing a calcium/calmodulin-529	
independent species [103]. Consistently, CAMK2G, was robustly activated by DTT, and 530	
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inhibited reversibly by H2O2 (Fig. 9H), suggesting a non Cys-activation segment mechanism 531	
of redox regulation for this kinase. In contrast, CAMK2D was completely resistant to changes 532	
in redox when assayed in the presence of Ca2+ and calmodulin (Fig. 9I), demonstrating that 533	
neither peroxide nor DTT act as non-specific regulatory factors for these recombinant kinases 534	
under our experimental conditions. Taken together, our data suggest that redox regulation is a 535	
conserved, reversible mechanism for multiple Ser/Thr protein kinases in vitro. 536	
Finally, we examined redox regulation in Tyr kinases, which with a few exceptions (Table 2), 537	
do not contain any conserved Cys residues in the activation segment, and as a family possess 538	
none at-all at the T-loop +2 position (Fig. 5B). The EPHA3 Tyr kinase domain was 539	
completely resistant to inhibition or activation by peroxide and DTT respectively (fig. S12A). 540	
ABL also lacks a T-loop Cys residue but is known to be susceptible to alternative modes of 541	
redox-dependent regulation [104]. Reversible inactivation of ABL by peroxide was also 542	
readily observed in our assays (fig. S12B). We next attempted to sensitize EPHA3 to Cys-543	
based redox regulation by incorporating Cys residues at equivalent positions in the activation 544	
segment (Fig. 5C). However, both G784C and a double mutant EPHA3 protein containing 545	
G783C and G784C substitutions remained unresponsive to peroxide or DTT (fig. S12D, E), 546	
whereas G783C EPHA3 lacked any detectable phosphotransferase activity (fig. S12C), 547	




Aurora A is a redox-sensitive Ser/Thr kinase 551	
In this study, we demonstrate that Aurora A is susceptible to reversible, oxidative-inactivation 552	
in vitro and in cells, by a mechanism that involves cysteine (Cys 290) located in the 553	
conserved activation loop, two amino acids C-terminal to the regulatory site of T288 554	
autophosphorylation.  555	
The nature of the oxidation events(s) in Aurora A are currently unclear. We employed 556	
an antibody with specificity towards Cys-SOHs that have been covalently derivatized with 557	
dimedone, to monitor alterations in Aurora A SOH content. These data unequivocally 558	
demonstrated direct oxidative modification of Aurora A at Cys residues after exposure to 559	
H2O2 resulting in an increase in total protein sulfenylation (Fig. 2). Interestingly, not all Cys 560	
residues are equally susceptible to oxidation in proteins, with those that have a functional role 561	
in redox-dependent signaling often possessing a low pKa value of approximately 5.0 [105]. 562	
Moreover, the solvent accessibility and the structural micro-environment impact the reactivity 563	
of Cys-residues [66, 105]. In addition to SOH, reversible Cys-sulfenamides have also been 564	
implicated as targets of dimedone adduct formation, and we are currently undertaking 565	
detailed investigation to formally distinguish between these two reversibly oxidized thiol 566	
species [11] in Aurora A. Direct S-glutathionylation of Aurora A was also detected at Cys 290 567	
(Fig. 3), which is consistent with disulfide exchange between GSSG and reactive Cys 568	
thiolates in the kinase that can stabilize the partially oxidized sulfenic form by formation of a 569	
disulfide with Cys in glutathione ion order to prevent irreversible oxidation (fig. S1). The 570	
presence of sulfenylated (or sulfenamide) Cys in Aurora A was of particular interest, since 571	
this is a reversible Cys-modification and might therefore function as a bona fide signaling 572	
mechanism in response to cellular oxidative stress, as previously described PTP1B [22]. Our 573	
observation that C290A Aurora A was still modified by dimedone, albeit to a lesser extent 574	
than for control Aurora A (Fig. 2C), provides evidence for the existence of additional redox 575	
active Cys residues, although their relevance for regulating catalytic activity appears to be 576	
minor and we establish here that Cys290 is required for oxidation and inhibition of Aurora A. 577	
Interestingly, a very recent study found that Aurora A can be covalently modified by the 578	
sulfhydryl moiety of the Cys-containing metabolite CoA under appropriate redox conditions, 579	
and that an intermolecular disulfide bond with Cys 290 in an adjacent Aurora A might 580	
contribute to an oxidative mechanism of inhibition [106]. Future work will evaluate the 581	
relative contribution of disulfide bond formation in this, and other, redox-sensitive Ser/Thr 582	
kinases analysed in this paper.  583	
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Using Cy-preds [66], which combines structural energetics and similarity-based 584	
considerations, we identified Cys 290 in Aurora A as a very high-probability target for 585	
oxidation. The location of this residue on the activation loop (or T-loop) of Aurora A is 586	
notable, as this region is a well-known regulatory locus for the modulation of catalytic 587	
activity in many eukaryotic protein kinases [107, 108]. We propose that Cys 290 in Aurora A 588	
is strategically positioned to trigger a regulatory response to ROS, or for protection from 589	
over-oxidation by covalent glutathionylation. This hypothesis has previously been explored 590	
for equivalent activation loop Cys residues including Cys 200 of PKA [59, 71], Cys 310 of 591	
AKT [109], Cys174 of AMPK [34], and Cys179 of CAMK1 [102]. Structural analyis of AKT 592	
previously described an oxidized intramolecular species, likely to be the catalytically-inactive 593	
version present upon exposure to peroxide in our studies (Fig. 8A and fig. S13). Together, our 594	
findings establish Cys 290 as a likely target of oxidative modification and a dominant 595	
coordinator of redox regulation in Aurora A. Although it is unlikely that Cys 290 directly 596	
participates in substrate phosphorylation by Aurora A, maintaining a reduced sulfhydryl at 597	
this position appears to be required for enzyme activity in the absence of allosteric regulators 598	
such as TPX2, which serve to protect Aurora A from oxidative inhibition in vitro (Fig. 2).  599	
Cellular modulation of Aurora A activity by reversible oxidation. 600	
The findings from our biochemical studies are strongly supported by cellular data. We 601	
observed inhibition of TACC3 Ser558 phosphorylation (a physiological marker of Aurora A 602	
activity) in cells exposed to both oxidants and inducers of oxidation (Fig. 4). In addition, 603	
inhibition of Aurora A by H2O2 could be blocked by including ROS-scavengers such as NAC 604	
and GSH in the culture medium, either restoring oxidized Aurora A back to a reduced, 605	
catalytically-active state or by protection of Aurora A from over-oxidation (Fig. 2). The 606	
inability of DTT to restore Aurora A activity in vivo likely reflecting its profound cellular 607	
effects on the oxidation state of ER proteins and subsequent enhanced ROS generation as part 608	
of the unfolded protein response[110]. Furthermore, phosphorylation of exogenous TACC3 609	
under highly oxidative conditions could be induced through transient co-expression with a 610	
‘redox-resistant’ C290A Aurora A mutant, supporting a physiological regulatory role for the 611	
T-loop +2 Cys residue in a cellular context. Interestingly, oxidative stress has been shown to 612	
impede mitotic progression of cells via a number of different mechanisms [111, 112]. To 613	
ensure that changes in signaling were a direct consequence of oxidative modification of 614	
Aurora A, and not just due to cell cycle inactivation of the kinase, all of our experiments were 615	
performed using synchronized cells arrested in mitosis with nocodazole [5]. Previous 616	
observations demonstrated hyperphosphorylation of Aurora A at Thr 288 in HeLa cells under 617	
oxidative stress [113], which was proposed as a mechanism for ROS-induced mitotic arrest. 618	
Although Thr 288 autophosphorylation is a kinase-activating prerequisite (Figure 1), a 619	
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growing body of evidence suggests that monitoring this phosphorylation site is not ideal for 620	
reporting Aurora A catalytic activity in cells [114]. In this regard, it is noteworthy that 621	
phosphorylated Thr 288 can also potentially be generated by non-autophosphorylation 622	
mechanisms [115, 116], whose sensitivity to redox regulation may differ. Furthermore, 623	
Aurora A regulation is a dynamic, multi-layered process involving several regulatory steps 624	
that are uncoupled from autophosphorylation, including allosteric activating complexes 625	
formed with non-catalytic protein binding partners [117]. Based on our data, we propose that 626	
Aurora A-dependent phosphorylation of TACC3 at Ser 558 is an ideal biomarker for 627	
reporting Aurora A redox-regulated activity, since Aurora A is the only kinase known to 628	
target this site physiologically. In support of this finding, an increase in Aurora A 629	
autophosphorylation and CoAlation is also found in cells treated with inducers of oxidative 630	
stress	 [118]. Regardless of the mechanism, complex spatio-temporal regulation means that 631	
caution should be applied when interpreting changes in cellular Aurora A catalytic outputs, 632	
especially if changes in the redox environment are induced or suspected. 633	
A conserved propensity for Ser/Thr kinase regulation by redox? 634	
The redox regulation of signaling enzymes is a rapidly expanding field of study. Whereas the 635	
majority of early research focused on the indirect targeting of kinases through oxidative 636	
inhibition of protein tyrosine phosphatases [105], there is now a wealth of evidence detailing 637	
direct oxidation of Cys and Met residues in protein kinases, where diversity within kinase 638	
groups and subfamilies has been reported [119, 120]. However, although Cys-dependent 639	
redox regulation has been described within stress-activated protein kinase modules, including 640	
thioredoxin-regulated ASK1 [32, 121, 122], MEKK1 [123], MKK6 [124], and glutathione-641	
responsive JNK and p38a-MAPK [125], to our knowledge, no conserved mechanism has 642	
been described. Moreover, none of these redox-regulated human MAPK, MAPKK and 643	
MAPKKKs contain this conserved activation segment Cys residue (Table 2), in contrast to 644	
the p38-MAPK targets MAPKAP-K2 and MAPKAP-K3, which we demonstrate are rapidly 645	
inactivated by oxidation in vitro (Fig. 8).   646	
Evolutionary bioinformatics reveals that Cys is widespread in ePKs. 647	
Our comparative evolutionary analysis of protein kinomes revealed that ~11.5 % of all 648	
protein kinases contain an analogous Cys residue to Cys 290 in Aurora A (equivalent to Cys 649	
200 in PKA) at the ‘T-loop +2 position’ in the activation segment (Fig. 5). However, only 650	
specific members of the AGC and CAMK sub-families were enriched for this conserved Cys 651	
residue. This prompted us to investigate redox-sensitivity in a selection of kinases containing 652	
a conserved T-loop Cys. Of 17 ‘T-loop +2 Cys’-containing kinases investigated, 13 were 653	
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susceptible to reversible oxidative modulation. These included kinases for which redox-654	
sensitivity had previously been noted, including AKT, AMPK, MELK and CAMK1, as well 655	
as totally novel targets of oxidative modification, including SIK1-3, PLK1, PLK4 and 656	
MAPKAP-K2/3. We were also able to directly attribute redox-inhibition in the T-loop + 2 657	
Cys residue in MAPKAP-K2 and PLK1 through comparative analysis of WT and Cys-Ala 658	
mutant proteins purified from human cells (Fig. 7). Intriguingly, some kinases that were 659	
predicted to be redox-sensitive based on the presence of the appropriate Cys-residue in the 660	
activation segment, such as Protein Kinase G (PKG) and Phosphorylase Kinase (PhK), were 661	
resistant to peroxide inhibition, under identical experimental redox conditions that led to 662	
reversible modulation of other kinases.  However, these (and other) kinases may still be 663	
sensitive to oxidation in cells, where peroxiredoxins have been shown to act as peroxide 664	
signal relays for kinases [126] and other proteins [127] A lack of chemical reactivity in an 665	
activation segment Cys might partially explain this observation, as observed for GAPDH 666	
[128], and also nicely demonstrates that the concentrations of redox reagents in our standard 667	
assay do not induce effects through a non-specific mechanism, such as protein denaturation. 668	
The intrinsic pKa value of individual Cys residues, and their susceptibility to oxidation, is 669	
influenced by networks of interacting amino acids, solvent accessibility, protein-protein 670	
interactions and structural dynamics [66, 129]. In this context, artificial incorporating of a Cys 671	
residue at the equivalent position in EPHA3 did not sensitize this Tyr kinase to oxidation (fig. 672	
S12), suggesting that the EPHA3 activation loop is potentially in an unfavourable 673	
environment to stabilize reactive Cys residues. Moreover, the relative reactivity of a Cys-674	
residue is likely to be context-specific and could vary between different allosteric activation 675	
states. In this regard, it is noteworthy that Cys 290 transitions from being exposed, to buried, 676	
in TPX2-bound Aurora A [118], although it is not immediately obvious to what extent this 677	
reconfiguration translates to a reversible change in Cys reactivity. 678	
The Cys-containing regulatory activation segment in ePKs. 679	
The conserved location of the specific Cys residue studied in this study is rather specific to 680	
CAMK and AGC families of  ePKs, although well-studied groups of kinases in these families 681	
such as G-protein coupled kinases (GPRKs), PDK1, NDR/LATS kinases, MLCKs or DAPKs, 682	
do not possess an evolutionary-conserved Cys at the Cys 290 equivalent of Aurora A. Closer 683	
inspection of the activation segment confirms that although Cys is present at all possible 684	
positions in the activation segment across various kinomes (fig. S8F), two sites, DFG +2 685	
(5.1%) and T-loop +2 (11.5%) dominate evolutionary Cys conservation in this region. 686	
Interestingly, both Cys residues acids are co-conserved in ~1.4% of all ePKs in our database 687	
(Fig. 5A, bottom panel), where in the context of redox regulation, they are believed to support 688	
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intramolecular and/or intermolecular disulfide bonds in AKT, MELK (and perhaps PAKs, 689	
p70S6k and PKC isozymes Table 2 and fig. S13). Consistent with this prediction, the 690	
introduction of a Cys residue at the DFG + 2 position in Aurora A changed both thermal 691	
stability and redox regulation so that it behaved much more like AKT and MELK. Moreover, 692	
we obtained MS data that confirmed the formation of an intermolecular disulfide bond 693	
between Cys 290 and the newly introduced Cys 278 (Fig. 7G), which likely explains the 694	
acquired obligate dependency on reducing agents to activate S278C Aurora A.  695	
The kinase activation segment contains multiple conserved residues available for post-696	
translational phosphorylation in protein kinases [130-133], and serves as a critical regulatory 697	
structure for the modulation of catalytic activity [19]. The activation loop of Aurora A itself 698	
undergoes dynamic conformational changes in response to phosphorylation and interactions 699	
with allosteric binding-partners, enabling Aurora A to transition between alternate active 700	
states [134]. This structural plasticity is perhaps most apparent when considering the number 701	
of distinct Aurora A conformations that have been captured in complex with small molecule 702	
inhibitors by crystallographic and NMR based techniques [135-138]. Even in an active, 703	
phosphorylated form, the activation loop of Aurora A possesses a dynamic conformational 704	
ensemble of ‘DFG-in’ sub-states [75, 139]. We postulate that oxidation of Cys 290, or 705	
equivalent Cys residues in the activation segment. Alternatively, their oxidation could 706	
generate higher-order molecular species such as inhibitory dimers. The observation that 707	
activation by TPX2 binding to Aurora A supersedes oxidative inhibition is consistent with 708	
this explanation, given that inactive (e.g Thr 288 dephosphorylated) Aurora A assumes an 709	
active conformation when it is bound to TPX2 [75]. Aurora A activity is also reversibly 710	
inhibited by CoAlation on Cys 290, and this modification has also been reported in human 711	
cells exposed to a variety of oxidative stresses, where Aurora A dimerization represents a 712	
potential mechanism for redox regulation [118].  713	
 714	
Further structural and proteomics efforts are required to decipher the molecular and structural 715	
processes involved in oxidative regulation of protein kinases and to assess the relative 716	
contribution of different reversible Cys oxidized states (e.g sulfenic acids, sulfenyl-amides, 717	
intra-and intermolecular disulfide bonds) in modulating function. The proximity of conserved 718	
Cys residues in ePKs is known to enable a regulatory intramolecular disulfide bond to form, 719	
including Cys296 and Cys310 in the auto-inhibited conformation of AKT and Cys153 and 720	
Cys 168 of MELK [99, 109, 140]. Our studies with MELK also point to a plausible 721	
mechanistic explanation for the oxidative inactivation of structurally homologous kinases 722	
through dimerization (fig. S13), as observed for the S278C mutant of Aurora A. Although 723	
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MELK activity exhibits an obligate dependence on the presence of reducing agents [97], 724	
elimination of the intramolecular disulfide bond by double mutation of both Cys residues 725	
releases MELK from this regulatory requirement [140]. Interestingly, in our experiments 726	
removal of either Cys168 or Cys169 (the latter of which represents the T+2 Cys) was 727	
insufficient to abolish redox dependent activation of MELK, which potentially indicates a 728	
redundancy in the ability of both residues to form a disulfide bond with Cys153. This was 729	
substantiated with a double Cys168/169 MELK mutant, which was no longer activated by 730	
DTT. For T-loop +2 Cys kinases that lack a complementary Cys residues with which an 731	
intramolecular disulfide bond could form, the molecular mechanisms of redox based 732	
regulation are less apparent, although we cannot discount inter- or intradisulfide bond 733	
formation between other, as yet uncharacterized Cys residues in the activation segment (Table 734	
2) or beyond. Finally, our recent work demonstrates that the evolutionary-related prokaryotic 735	
and eukaryotic Fructosamine 3 kinases (FN3Ks), which lack the conventional activation 736	
segment found in the Ser/Thr kinases described here, also employ reversible Cys regulatory 737	
mechanisms to control catalytic output [141]. Indeed, like many human Tyr kinases, FN3K’s 738	
possess conserved redox-active Cys residues in the Gly-rich loop that function as oxidizable 739	
switches to co-ordinate reversible dimerization and control enzymatic (in)activation.  740	
CONCLUSIONS: 741	
In this paper, we describe a new mechanism for the oxidative modulation of Aurroa A kinase 742	
activity involving a structurally-conserved redox active Cys residue located on the activation 743	
loop. Due to a central role in controlling catalytic output through phosphorylation, this region 744	
of kinases has been heavily investigated as a regulatory hot-spot. Our new findings suggest 745	
that Cys oxidation and reduction can act dominantly over T-loop phosphorylation, providing 746	
an additional phosphorylation-independent layer of control over enzyme activity that might 747	
be important in eukaryotic cells. The activation segment has been exploited for the generation 748	
of many phosphospecific antibodies for biological evaluation of CAMK and AGC kinases. To 749	
our knowledge, the effects of Cys redox status have not been tested in the context of 750	
phosphospecific antibody protocols, and in most cases, Cys residues in proteins are reduced 751	
by boiling in buffer containing a reducing agent prior to SDS-PAGE. However, our work 752	
demonstrates the vulnerability of Cys residues to redox modification in human AGC and 753	
CAM kinases, which impinges directly on catalytic output, and that might also impact on the 754	
ability of antibodies to accurately monitor phosphorylation status of the activation segment 755	
under certain circumstances.  756	
This study opens new investigative avenues to explore the functional relationship between 757	
physiological ROS-based signaling networks and the broader redox-regulated kinome, 758	
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especially mechanisms that occur through conserved activation-segment Cys residues in 759	
eukaryotic kinases. Mitochondrial damage and the associated elevation of ROS is implicated 760	
in a range of human diseases including ageing [142], cancer [143] and neural degenerative 761	
disorders such as Parkinson’s disease [144] and a multitude of factors, including hypoxia, 762	
contribute to sustained high ROS levels in tumours [145]. A key line of enquiry, therefore, 763	
will be to explore the impact of chronic oxidative stress and increased sulfenylated-protein 764	
populations on both normal and pathological Ser/Thr kinase function. The extent to which 765	
oxidation of kinases may influence the therapeutic efficacy of inhibitor compounds in a 766	
cellular context is also of interest, especially for kinases targeted by Cys-based covalent 767	
mechanisms. Indeed, different Aurora A inhibitors target distinct conformational species, 768	
which can be broadly separated into compounds with preferences for the DFG-in or DFG-out 769	
states [75, 137, 138]. The ability of oxidative modifications in the activation segment to alter 770	
this ‘DFG equilibrium’ may also have implications for the selectivity of inhibitors in cells, 771	
where the propensity of redox-active Cys residues in Ser/Thr kinases to undergo sulfenylation 772	
could be exploited for the rationale design new classes of covalent inhibitors. This strategy 773	
has been adapted to great success to generate clinical compounds with potency and selectivity 774	
towards tyrosine kinases, such as afatinib and neratinib, which target Cys797 of the redox-775	
regulated tyrosine kinase EGFR for the treatment of non-small cell lung cancer [146]. Finally, 776	
a deeper mechanistic understanding of the dynamics of Ser/Thr kinase redox regulation, may 777	
reveal Cys residues that are differentially exposed in active and inactive kinase conformations 778	
and potentially lead to a diverse and versatile reservoir of specific drug targets [147].  779	
  780	
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MATERIALS AND METHODS: 781	
Commercial recombinant protein kinase fusion proteins were purchased from MRC PPUU 782	
reagents (University of Dundee), and were purified from Sf21 cells or E. coli. Full details are 783	
provided in Table 2. GST and 6His-tagged kinases were purified using standard procedures, 784	
prior to storage in 1 mM DTT (except where indicated) at -80°C. All kinases were assayed 785	
using standard enzyme preparations [148]. Bacterially-expressed GST-MAPKAP-K2 and 786	
GST-MAPKAP-K3 were activated in vitro by incubation with catalytically-active p38a, 787	
which was removed by re-purification prior to assay. General biochemicals and all redox 788	
reagents, including glutaredoxin (GRX), were purchased from Sigma-Aldrich. 789	
 790	
Protein kinase assays 791	
Kinase assays were performed using non-radioactive real-time mobility shift-based 792	
microfluidic assays, as described previously [68, 93, 130, 149] in the presence of 2 µM of 793	
the appropriate fluorescent-tagged peptide substrate (Table 2) and 1 mM ATP. Pressure 794	
and voltage settings were adjusted manually to afford optimal separation of 795	
phosphorylated and non-phosphorylated peptides. All assays were performed in 50 mM 796	
HEPES (pH 7.4), 0.015% (v/v) Brij-35, and 5 mM MgCl2, and the real-time or endpoint 797	
degree of peptide phosphorylation was calculated by differentiating the ratio of the 798	
phosphopeptide:peptide present in the reaction. Kinase activity in the presence of different 799	
redox reagents was quantified by monitoring the generation of phosphopeptide during the 800	
assay, relative to controls. Data were normalised with respect to control assays, with 801	
phosphate incorporation into the peptide generally limited to 20% to prevent depletion of 802	
ATP and to ensure assay linearity. ATP KM and the concentration of a compound that 803	
caused 50% inhibition (IC50) values were determined by nonlinear regression analysis 804	
using Graphpad Prism software. Where specified, kinase assays employing Aurora A were 805	
supplemented with 100 nM GST-TPX2 or GST alone. Assays for CAMK kinases included 806	
5 mM CaCl2 and 2 µM Calmodulin as standard. Where appropriate, PKG1 assays were 807	
performed in the presence of 1 mM cGMP.  Recovery of Aurora A activity from oxidative 808	
inhibition was assessed by monitoring substrate phosphorylation in the presence of 809	
peroxide in real time, followed by subsequent introduction of DTT or GSH. To 810	
standardize this assay for all kinases, enzymes were pre-incubated in the presence or 811	
absence of 5 mM H2O2 on ice for 30 mins and then substrate phosphorylation was initiated 812	
with the addition of 1 mM ATP and the appropriate substrate peptide in the presence 813	
(where indicated) of 10 mM DTT. Aurora A kinase assays were also developed with 814	
recombinant GST-TACC3 as a substrate. TACC3 Ser 558 phosphorylation was detected 815	
by immunoblotting with a pSer 558 TACC3 antibody, as previously described [77]. 816	
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Aurora A autophosphorylation after phosphatase-treatment was detected using a Thr 288 817	
phosphospecific antibody [77]. 818	
 819	
Cloning and Recombinant Protein purification  820	
For enzyme and DSF assays, murine or human Aurora A, MELK (1-340), PLK1 (1-364), 821	
PLK4 (1-369), full-length PKA, EPHA3 (kinase domain and juxtamembrane region), ABL 822	
(46-515), TACC3 and TPX2(1-43) were produced in BL21 (DE3) pLysS E. coli cells 823	
(Novagen) with expression induced with 0.5 mM IPTG for 18 h at 18°C and purified as N-824	
terminal His6-tag or N-terminal His6-GST tag fusion proteins by affinity chromatography 825	
and size exclusion chromatography using a HiLoad 16/600 Superdex 200 column (GE 826	
Healthcare) equilibrated in 50 mM Tris/HCl, pH 7.4, 100 mM NaCl and 10 % (v/v) 827	
glycerol.  Where appropriate, recombinant protein was purified in the presence of 1 mM 828	
DTT. Ser278Ala, Ser278Cys, Cys290Ala Aurora A and equivalent Cys-Ala mutants of 829	
other kinases were generated using standard mutagenic procedures, and purified as 830	
described above [68]. To generate a phosphorylation-depleted kinase, Aurora A was co-831	
expressed with lambda phosphatase in BL21 (DE3) pLysS E. coli cells prior to 832	
purification; lambda phosphatase was subsequently removed by IMAC. 833	
Differential Scanning Fluorimetry  834	
Thermal-shift assays were performed with a StepOnePlus Real-Time PCR machine (Life 835	
Technologies) using Sypro-Orange dye (Invitrogen) and thermal ramping (0.3 °C in step 836	
intervals between 25 and 94°C). All proteins were diluted to a final concentration of 5 µM 837	
in 50 mM Tris/HCl, pH 7.4 and 100 mM NaCl in the presence or absence of the indicated 838	
concentrations of ATP, H2O2, DTT, GSH or MLN8237 (final DMSO concentration no 839	
higher than 4 % v/v) [150] and were assayed as described previously [69]. Normalized 840	
data were processed using the Boltzmann equation to generate sigmoidal denaturation 841	
curves, and average Tm/∆Tm values calculated as previously described [151] using 842	
GraphPad Prism software.  843	
Human cell culture and cell treatments 844	
HeLa cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Lonza) 845	
supplemented with 10% foetal bovine serum (FBS) (Hyclone), 50 U/ml penicillin and 0.25 846	
µg/ml streptomycin (Lonza) and maintained at 37 °C in 5 % CO2 humidified atmosphere. 847	
To examine the effects of oxidative stress on Aurora A kinase activity, cells were arrested 848	
in mitosis with 100 nM nocodazole for 16h, then treated with a range of concentrations of 849	
H2O2, menadione, or diamide for 30-60 min. To stimulate chronic oxidative stress, 850	
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arrested HeLa cells were collected, washed in PBS, and fresh culture medium containing 851	
glucose oxidase at a non-toxic concentration (2 U/ml) and 100 nM nocodazole was added. 852	
Subsequently, cells were collected and harvested periodically over a 2 h time period. To 853	
investigate reversible inactivation of Aurora A by peroxide, arrested cells were incubated 854	
for 10 mins with 10 mM H2O2, and then peroxide-containing medium was removed and 855	
replaced with fresh culture medium containing 10 mM DTT, NAC or GSH or buffer 856	
control. To examine TACC3 phosphorylation by exogenous Aurora A, HeLa cells were 857	
transfected with pcDNA3 encoding full length WT or C290A N-terminal Myc-tagged 858	
Aurora A and pBrain-GFP-TACC3KDP-shTACC3 (to simultaneously express N-terminal 859	
tagged GFP-TACC3 and supress expression of endogenous TACC3, Addgene), using 860	
Lipofectamine 3000 (ThermoFisher), and to simultaneously express N-terminal tagged 861	
GFP-TACC3 and supress expression of endogenous TACC3. 3 µg of DNA (for each 862	
plasmid) was used to transfect six well plate dishes of HeLa cells and the media was 863	
changed after 3 h. Equal volumes of transfection reagent were used for both single- and 864	
cotransfections. Transfected HeLa cells were synchronized with nocodazole as previously 865	
described 24 h after transfection. In all assays cells were subsequently washed in PBS and 866	
harvested in bromophenol blue-free SDS sample buffer supplemented with 1% Triton X-867	
100, protease inhibitor cocktail tablet and a phosphatase inhibitor tablet (Roche) and 868	
sonicated briefly prior to immunoblotting.  869	
Human cell lysis, immunoprecipitation and Western blot analysis 870	
Total cell lysates were centrifuged at 20817x g for 20 min at 4˚C and the supernatant was 871	
preserved for further analysis. Samples were initially diluted 50-fold and protein 872	
concentration was measured using the Coomassie Plus staining reagent (Bradford) Assay 873	
Kit (Thermo Scientific) and processed for immunblotting with TACC3 or Aurora A 874	
antibodies as described [77, 92]. To assay the kinase activity of T-loop + 2 Cys containing 875	
kinases immunoprecipitated from human cells, WT and Cys-Ala full length variants of 876	
MAPKAP-K2 and PLK1 (C244A and C212A respectively) were cloned into a pcDNA3 877	
vector and expressed with a 3C-protease cleavable, N-terminal Myc tag. All 878	
immunoprecipitation experiments utilised HEK 293T cells transfected using a 3:1 879	
Polyethylenimine (PEI, average Mw ~25,000 Da, Sigma) to DNA ratio (60:20 µg, for a 880	
single 10 cm culture dish). Cells were treated with 4 mM Valproic acid 24 h after 881	
transfection and proteins were harvested the following day using a lysis buffer containing 882	
50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 0.1 % (v/v) Triton X-100, and 5 % (v/v) glycerol 883	
and supplemented with a protease inhibitor cocktail tablet and a phosphatase inhibitor 884	
tablet (Roche). Lysates were briefly sonicated on ice, clarified by centrifuged at 20817x g 885	
for 20 min at 4˚C and the resulting supernatants were incubated with Pierce Anti-c-Myc-886	
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Agarose resin (ThermoFisher) for 1 h with gentle end-over end mixing at 4˚C. Agarose 887	
beads containing bound protein were collected and washed three times in 50 mM 888	
Tris/HCl, pH 7.4, and 500 mM NaCl and then equilibrated in storage buffer, 50 mM 889	
Tris/HCl,  pH 7.4, 100 mM NaCl and 5 % (v/v) glycerol. The purified kinases were then 890	
proteolytically eluted from the beads over a 3 h period using 3C protease (0.5 µg) at 4˚C 891	
with gentle agitation, and then assayed as previously described.  892	
Detection of sulfenylated and glutathionylated proteins by immunoblotting 893	
Recombinant Aurora A was incubated with 50 mM Tris/HCl, pH 7.4, and 100 mM NaCl 894	
in the presence of different concentrations of H2O2 or 10 mM DTT for 10 min. Cysteine 895	
sulfenic acid was detected by SDS-PAGE and immunoblotting after adduct formation with 896	
1 mM dimedone for 20 mins at RT. Dimedone stocks were prepared in DMSO with a final 897	
assay DMSO concentration no higher than 4 % (v/v).  To detect glutathionylation of 898	
proteins, proteins were incubated with 10 mM GSSG or GSH for 30 mins and glutathione-899	
protein complexes were detected by immunoblotting after non-reducing SDS-PAGE.   900	
MS analysis of intermolecular disulfide bond formation in S278C Aurora A 901	
Aurora A sample preparation 902	
5 µg of Aurora A purified in the absence of DTT was heated at 80 oC in 0.06% (w/v) 903	
RapiGest SF (Waters), dissolved in 25 mM ammonium bicarbonate, for 10 min. Sample was 904	
digested overnight at 25 oC using a 20:1 (w/w) ratio of Aurora A:Chymotrypsin (Promega), 905	
with 600 rpm shaking. The sample was equally split into 2, one aliquot of which was reduced 906	
with dithiothreitol (DTT) (3 mM) at 60 oC for 10 min, cooled and alkylated with 907	
iodoacetamide (IAA) (10 mM) at room temperature for 30 min in dark. Excess IAA was 908	
quenched by addition of DTT to a final concentration of 7 mM. The second sample was left 909	
on ice. RapiGest hydrolysis was induced in both samples by the addition of 1.5% (v/v) 910	
trifluoroacetic acid (TFA), 3% (v/v) acetonitrile, shaking at 600 rpm, 37 oC for 2 hr. Insoluble 911	
products were removed by centrifugation (13 000 g, 15 min 4 oC). Samples were subjected to 912	
strong cation exchange using in-house packed stage tips (Empore™ Supelco 47 mm Cation 913	
Exchange disc #2251), 3 discs per 200 µL tip. All centrifugation steps were performed at 914	
2000 g for 3 min, or until all liquid had passed through the stage tip. Briefly, tips were 915	
equilibrated by the sequential washing of 2X 200 µL of each: acetone, methanol, water, 5% 916	
(v/v) ammonium hydroxide (in water) and water. Peptide samples were passed through the 917	
equilibrated stage tip 3X and washed with 250 µL 1.5% (v/v) TFA in water, before eluting in 918	
250 µL of 5% (v/v) ammonium hydroxide (in water). Eluted material was dried to completion 919	
under cooled vacuum centrifugation. Peptides were solubilised in 20 µL 97% water, 3% (v/v) 920	
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acetonitrile, 0.1% (v/v) TFA and sonicated for 10 min before centrifugation (13 000 g, 15 min 921	
4 oC) to remove insoluble material prior to liquid chromatography-tandem mass spectrometry 922	
analysis. 923	
Liquid chromatography mass spectrometry analysis of WT and S278C Aurora A 924	
Peptides were separated on a Ultimate 3000 nano system (Dionex), by reverse-phase HPLC, 925	
using a trapping column (PepMap100, C18, 300 µm x 5 mm) in loading buffer (3% (v/v) 926	
acetonitrile, 0.1% (v/v) TFA) at a flow rate of 9 µL/min for 7 minutes. Chromatographic 927	
separation was performed using Easy Spray C18 column (75 µm x 500 mm, 2 µm bead 928	
diameter) at a flow rate of 0.3 µL/min over a 30 min gradient of 3% buffer A (0.1% (v/v) 929	
Formic acid in water): 97% buffer B (80% (v/v) acetonitrile, 0.1% (v/v) Formic acid in water) 930	
to 20% buffer A: 80% buffer B. Data was acquired using a Thermo Orbitrap Fusion Lumos 931	
Tribrid mass spectrometer (Thermo Scientific). All spectra were acquired in the Orbitrap in a 932	
data-dependent analysis mode using a top speed approach (cycle time 3 s), with ions being 933	
subjected to HCD (normalised collision energy (NCE) of 32%). MS1 parameters: 60K 934	
resolution at 200 m/z, automatic gain control (AGC) = 4e5, maximum injection time = 50 ms, 935	
mass range = 350 – 2000, charge stated 2+ - 6+. MS2 parameters: 30K resolution at 200 m/z, 936	
AGC = 5e4, maximum injection time = 54 ms. A dynamic exclusion window was applied for 937	
60 s at a tolerance of 10 ppm. 938	
MS Data analysis 939	
pLink-SS software was used to initially identify spectra containing disulfide linked peptides, 940	
as described	 [152]. Precursor and fragment tolerances were set to 10 ppm, variable 941	
modifications of Cys carbamidomethylation and Ser/Thr phosphorylation. Once a spectra 942	
containing a disulfide linked peptide was identified, the spectra was redrawn using a custom 943	
R script and manually annotated to include disulfide fragmentation mass shifts (-33.987 amu 944	
(dehydroalanine) and +31.971 amu (disulfohydryl) at both Cys residues	[153]. 945	
 946	
Identification, alignment and visualization of protein kinase-related sequences 947	
The MAPGAPS procedure [154] was employed alongside a variety of curated eukaryotic 948	
protein kinases profiles [130, 155-157] to identify and align eukaryotic protein kinase-related 949	
sequences from the non-redundant (NR) sequence database and UniProt reference proteome 950	
[158] databases (Release 2018_09). Sequences with a Cys residue at the Aurora A Cys290 951	
equivalent position were retrieved and used for further taxonomic analysis. Taxonomic 952	
information was based on NCBI Taxonomy database [159]. Weblogo’s [160] and were 953	
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generated using Weblogo Version 2.8. Amino acids were coloured based on their chemical 954	
properties. Polar amino acids (G,S,T,Y,C,Q,N) are colored green, basic (K,R,H) blue, acidic 955	
(D,E) red, and hydrophobic (A,V,L,I,P,W,M) black.  956	
Yeast strains and growth conditions 957	
S. pombe cells (Table 4) were transformed with the indicated plasmids and grown at 30oC in 958	
synthetic minimal medium (Edinburgh minimal medium 2) supplemented with 100 mg/l 959	




The wild-type srk1 gene (including intron) was amplified from S. pombe genomic DNA by 964	
pcr and srkC324A, and srk1C324S were generated synthetically, PCR-amplified and ligated into 965	
NdeI and BamHI sites in pRep41HM [161] to generate pRep41HMsrk1, pRep41HMsrkC324A, 966	
and pRep41HMsrkC324A expressing HisMyc-tagged Srk1, Srk1C324A or Srk1C324S from the 967	
nmt41 promoter. Wild type pka1 open reading frame, without the stop codon, was amplified 968	
from S. pombe genomic DNA and cloned into pJet1.2. pka1C358S was amplified from genomic 969	
DNA by a two-step overlapping PCR to introduce the mutation. Pka1C358A was generated 970	
synthetically. Wild-type and pka1 mutant genes were then subcloned into NdeI and BamHI 971	
sites in pRep41pkC [161] to generate pRep41Pka1pkc, pRep41Pka1C358Spkc and 972	
pRep41Pka1C358Apkc expressing C-terminally Pk-tagged Pka1, Pka1C358S or Pka1C358A from 973	
the nmt41 promoter. All primer sequences are available upon request. 974	
Analysis of S. pombe proteins by immunoblotting  975	
Equal amount of exponentially growing cells (9×106-1×107cells) were added to 20% 976	
trichloroacetic acid (TCA), harvested by centrifugation at 3000rpm for 1min and then snap 977	
frozen in liquid nitrogen. Protein was extracted as described previously (Delaunay et al., 978	
2000) but without phosphatase treatment.  Proteins were resuspended in 1% SDS, 1mM 979	
EDTA, 100mM Tris-HCL pH 8.0 containing 10mM NEM (N-Ethymaleimide). Protein 980	
concentrations were estimated using the bicinchoninic acid protein assay (Thermo scientific) 981	
and equal amounts of protein (5-10µg) resolved on 8% SDS-PAGE gels, followed by 982	
transferred to nitrocellulose membrane and analysed as described [162] 6His-Myc-tagged 983	
Srk1 protein was detected using anti-myc antibodies (9E10, Santa Cruz). Anti-tubulin 984	
antibody (anti-Tat1) was used as a loading control. For detecting Pka1 phosphorylated 985	
substrates, membranes were blocked with 10% (w/v) BSA in TBST, incubated with Phospho 986	
PKA substrate (RRXS*/T*) (Cell signaling 100G7E) primary antibody diluted 1:1000 in 987	
TBST containing 5% (w/v) BSA and probed with HRP-conjugated anti rabbit (cell signaling) 988	
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secondary antibody, diluted 1:3000. For Pka1-Pk detection, anti-pk (Sigma-Aldrich V8012) 989	
primary antibody (1:1000) was applied followed by HRP-conjugated anti mouse antibody 990	
(Sigma) diluted 1:3000. Enhanced chemiluminescence (PierceTM ECL Plus, Thermo 991	
Scientific) and ImageQuant Software (Typhoon FLA9500) or Vilber Fx6 / Fx7 992	
Chemiluminescent System (Labtech) was used to image fluorescence.  993	
 994	
Analysis of S. pombe cell length at division and CDC25GFP localisation  995	
Exponentially growing S. pombe were resuspended in phosphate-buffered saline, and 996	
mounted onto poly-L-lysine coated slides. DIC images were taken using a Zeiss Axioscope 997	
and cell lengths compared by measuring >94 newly divided cells for each sample. For 998	
analysis of fluorescence (CDC25GFP localisation), cells were mounted in Vectashield 999	
containing 1.5µg/ml DAPI to visualise DNA, and observed on a Zeiss Axioscope 1000	
fluorescence microscope using appropriate filters.  1001	
Assessing growth and salt stress sensitivity of S. pombe 1002	
Equal numbers of exponentially growing WT(JX333) or Dpka1(JX384) cells transformed 1003	
with pRep41pkc(vector), pRep41Pka1pkc, pRep41Pka1C358Spkc or pRep41Pka1C358Apkc  1004	
grown in EMM supplemented with 100mg/l adenine and 20µg/ml thiamine (EMMAT) were 1005	
serially diluted (10-fold dilutions then spotted onto EMMAT agar plate or EMMAT agar 1006	
plates containing 1M KCl). Plates were incubated at 30°C for 2-5 days and imaged at 24h 1007	
intervals until comparable levels of growth were observed for the WT cells on each plate.  1008	
 1009	
Statistical analysis 1010	
All experimental procedures were repeated in at least 3 separate experiments with matched 1011	
positive and negative controls (unless stated otherwise). Results are expressed as mean ± SD 1012	
for all in vitro experiments and data are expressed as the mean ± standard deviation. When 1013	
applied, statistical significance of differences (*P ≤0.05) was assessed using a Students t-test 1014	






Figure 1. Redox-dependent regulation of Aurora A activity in vitro. 1020	
(A) Dose response curves for the reducing reagent DTT (red) and the oxidizing agents H2O2 1021	
(blue) and diamide (green) with 6 nM recombinant Aurora A in the presence of 1 mM ATP. 1022	
Aurora A activity was assessed by monitoring phosphorylation of a fluorescent peptide 1023	
substrate, and normalized to controls after 30 min assay. (B) Immunoblot of an in vitro kinase 1024	
assay using recombinant GST-TACC3 as a substrate for Aurora A. Aurora A (3 ng ) was 1025	
incubated with the indicated concentrations of H2O2 and DTT or 0.1 mM of the Aurora A-1026	
specific inhibitor MLN8237 for 30 mins at 20 °C. The kinase assay was then initiated 1027	
following the addition of GST-TACC3 (1 µg) and Aurora A-dependent phosphorylation of 1028	
TACC3 (pSer558, top panel) was detected after 15 mins. 0.5 mM ATP and 5 mM MgCl2 1029	
were included in the reaction. Reactions were terminated by the addition of SDS loading 1030	
buffer. Equal loading of TACC3 substrate was confirmed with anti-TACC3 antibody (second 1031	
panel from top). Also shown is total (second panel from bottom) and phosphorylated Aurora 1032	
A (pThr 288, bottom panel). (C) Oxidative-inhibition of Aurora A is reversible. Aurora A 1033	
(12.5 nM) activity was monitored in real time in the presence (blue) or absence (black) of 1 1034	
mM H2O2 (left panel) or 10 µM MLN8237 (right panel). After 25 mins, reactions were 1035	
supplemented (where indicated) with 2 mM DTT (red). Aurora A dependent phosphorylation 1036	
of the fluorescent peptide substrate was monitored using assay conditions described in (A). 1037	
(D) Immunoblot demonstrating reversible increase in the electrophoretic mobility of Aurora 1038	
A, presumably due to oxidation by H2O2. Aurora A (0.5 µg) was incubated with the indicated 1039	
concentrations of H2O2 for 10 mins at 20°C and analysed after non-reducing or reducing 1040	
SDS-PAGE. Asterisk denotes the reversibly oxidized species found in the absence of DTT; 1041	
the identity of the more slowly migrating pT288-containing species in these samples is 1042	
unknown. Total Aurora A (upper panel) and pThr 288 Aurora A (lower panel) blots are also 1043	
shown. (E, F) Immunoblot demonstrating redox-dependent Aurora A autophosphorylation at 1044	
Thr 288. Dephosphorylated Aurora A (1 µg) was produced by co-expression with lambda 1045	
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phosphatase in E. coli and then incubated with 1 mM ATP and 10 mM MgCl2 for the 1046	
indicated time periods under reducing (+ 1 mM DTT) or oxidizing (+ 1 mM H2O2) conditions 1047	
in the presence and absence of TPX2 or MLN8237. Reactions were terminated by the 1048	
addition of SDS loading buffer.  1049	
 1050	
Figure 2. Conserved Cys 290 residue in the Aurora A activation loop is reversibly 1051	
oxidized in vitro: effect of TPX2. 1052	
(A) Detection of reactive cysteine oxidation in Aurora A with an antibody with specificity 1053	
towards cysteine sulfenic acids that have been derivatised by dimedone (SOH-Aurora A). 1054	
Aurora A (0.5 µg) was incubated with 1 mM H2O2 in the presence or absence of 1 mM 1055	
dimedone for 20 mins (all incubations performed at 20°C). Total Aurora A loading is also 1056	
shown (bottom panel).  (B) Concentration dependent oxidation of Aurora A detected by 1057	
dimedone. Aurora A (0.5 µg) was incubated with an increasing concentration of H2O2,10 mM 1058	
DTT or buffer alone for 10 min and then all samples were exposed to 1 mM dimedone for a 1059	
further 20 mins (all incubations performed at 20°C). (C) Immunoblot demonstrating depleted 1060	
total SOH content in Aurora A C290A compared to WT enzyme. Assay conditions are as 1061	
described for (B). (D) Comparative analysis of WT (red) and C290A (blue) Aurora A activity 1062	
in the presence of a fixed amount of ATP (1mM) and varying concentrations of H2O2 or (E) 1063	
DTT. Assays were performed using 6 nM Aurora A, and the extent of substrate 1064	
phosphorylation (presented here as activity normalized to controls containing buffer alone) 1065	
was determined after 60 mins assay time. (F) Redox regulation of PKA catalytic domain. WT 1066	
or C200A His-PKA (0.3 nM) were assayed with the indicated concentration of H2O2 or DTT 1067	
and activities were normalized relative to controls. (G) Reversible redox regulation of PKA.  1068	
(H) Structural disposition of the Aurora A activation segment (red). Cys 290 lies adjacent to 1069	
Thr 288, the site of Aurora A autophosphorylation. (I) Binding of TPX2 protects Aurora A 1070	
from inactivation by H2O2. H2O2 dose response curves are shown for Aurora A (6 nM) pre-1071	
incubated for 10 mins at 20 °C with or without 100 nM GST-TPX2 prior to oxidation with the 1072	
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indicated concentration of H2O2. Aurora A activity in the presence of 1 mM ATP was 1073	
normalised to buffer controls after 40 mins assay time. (J) TPX2-Aurora A kinase activity is 1074	
restored by DTT following oxidative-inhibition by H2O2. Substrate phosphorylation by 1075	
Aurora A (1 nM, with 100 nM GST-TPX2) was monitored in real time in the presence or 1076	
absence of 1 mM H2O2 for 50 mins prior to the addition of 2mM DTT to the indicated 1077	
reactions. Assays were started simultaneously with 100 µM ATP.  1078	
 1079	
Figure 3. Aurora A is activated by modification of Cys 290. 1080	
(A) Redox-dependent activation of Aurora A or (B) C290A Aurora A by a panel of reducing 1081	
agents. WT and C290A Aurora A proteins (12.5 nM) were incubated with 1 mM ATP in the 1082	
presence of 1 mM of the appropriate reducing agent and fluorescent peptide substrate. 1083	
Activity was calculated relative to a control (buffer only) after 40 mins assay time. (C) Dose 1084	
response curves for GSH. The activity of WT and C290A Aurora A (12.5 nM) was monitered 1085	
in the presence of increasing concentrations of GSH and 1 mM ATP. Aurora A activity was 1086	
normalised to buffer controls after 40 min assay time. (D) Immunoblot demonstrating in vitro 1087	
glutathionylation of Aurora A at Cys 290. 1 µg of recombinant purified WT and C290A 1088	
Aurora A proteins were incubated in the presence or absence of 10 mM GSSG for 30 mins at 1089	
20°C. Western blots were probed with an antibody with specificity towards glutathione-1090	
conjugated proteins. Equal loading of protein was confirmed using an antibody for Aurora A. 1091	
PKA (1 µg) was also included as a positive control. SDS-PAGE was performed under non-1092	
reducing conditions. (E) Inhibition of Aurora A by H2O2 is relieved by DTT but not GSH. 1093	
Aurora A (12.5 nM) activity was assayed in real time in the presence or absence of 1 mM 1094	
H2O2 for 50 mins and reactions were supplemented (where indicated) with 2 mM DTT (left 1095	
panel) or GSH (right panel). Aurora A-dependent phosphorylation of the fluorescent peptide 1096	
substrate was initiated by the addition of 1 mM ATP. (F) Immunoblot demonstrating 1097	
glutathionylation of AKT. 1 µg PDK1 phosphorylated S473D AKT was incubated with 100 1098	
µM H2O2 for 10 mins prior to the application of 1 mM GSH (30 mins at 20°C). SDS-PAGE 1099	
was performed under non-reducing conditions and 1 µg Aurora A was used as a positive 1100	
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control. (G) Activity of AKT is recapitulated by DTT but not GSH. The activity of PDK1 1101	
phosphorylated S473D AKT (7 nM) with 1 mM ATP was monitored in the presence of 1 mM 1102	
H2O2 for 40 mins prior to the addition of 2mM DTT (left panel) or GSH (right panel). 1103	
 1104	
Figure 4. Oxidation inhibits endogenous Aurora A activity in human cells. 1105	
(A) Treatment of HeLa cells with H2O2 results in a loss of TACC3 phosphorylation at Ser558. 1106	
Immunoblot shows a loss of Aurora A-dependent phosphorylation of TACC3 (pTACC3) in 1107	
HeLa cells untreated or treated with 10 mM H2O2 or 1 µM MLN8237 for 30 mins. (B) 1108	
Concentration dependent inhibition of endogenous Aurora A activity by H2O2. Immunoblots 1109	
show a loss of pTACC3 in HeLa cells incubated with the indicated concentration of H2O2 for 1110	
30 mins. A representative western blot of two independent experiments is shown. (C) 1111	
Concentration dependent inhibition of endogenous Aurora A activity by the oxidizing reagent 1112	
diamide and (D) redox-cycling quinone menadione. Loss of pTACC3 in HeLa cells incubated 1113	
with the indicated concentration of diamide for 30 mins or menadione for 60 mins. (E) Loss 1114	
of pTACC3 in HeLa cells exposed to glucose oxidase (GO). Immunoblots show time-1115	
dependent inhibition of TACC3 phosphorylation in HeLa cells cultured in the presence of 2 1116	
U/ml GO and nocodazole for the indicated time periods. (F) Aurora A oxidative-inhibition is 1117	
reversed by the peroxide scavengers, NAC and GSH. Immunoblots of HeLa cells treated with 1118	
10 mM H2O2 for 10 mins prior to the addition of fresh culture medium containing 10 mM 1119	
DTT, NAC or GSH or buffer control. Cells were then cultured for an additional 20 mins prior 1120	
to the extraction of whole cell lysates. In all experiments described here, HeLa cells had been 1121	
blocked in mitosis by nocodazole (100 ng/mL) for 16 h. Whole cell lysates were analysed by 1122	
western blot and probed with anti-TACC3 or anti-pSer558-TACC3 antibodies. Equal loading 1123	
was confirmed using antibodies against Aurora A and GAPDH. (G) Immunoblots showing 1124	
phosphorylation of GFP-TACC3 by Myc-Aurora A in co-transfected HeLa cells. Transiently 1125	
transfected HeLa cells containing plasmids for expression of EGFP, GFP-TACC3 and WT or 1126	
C290A Myc-Aurora A were cultured for 24 h and then arrested in mitosis with 100 nM 1127	
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nocodazole for 16h. HeLa cells were then incubated with the indicated concentration of 1128	
diamide for 30 mins and whole cell lysates were collected. 1129	
 1130	
Figure 5. Bioinformatic analysis of Aurora A Cys 290-equivalent in all ePKs. 1131	
(A) Analysis of ePKs, centered on the activation segment between the canonical DFG and 1132	
APE motifs. The amino acid distribution (percentage of all kinases) is shown on right, data 1133	
presented as HMM Sequence Logos. (B) Human Kinome dendrogram, showing highly 1134	
skewed distribution of kinases containing a Cys residue at the T-loop +2 residue in AGC and 1135	
CAML groups. (C) Activation segment alignment of human kinases analysed in this study. 1136	
 1137	
Figure 6. Cys 358 of S. pombe PKA (Pka1) is required for growth in high salt conditions 1138	
and Cys 324 is important for the anti-mitotic activity of S. pombe MAPKAP-K2/Srk1 in 1139	
promoting nuclear exclusion of CDC25. 1140	
(A) Sequence comparison between S. pombe Pka1 and MAPKAP-K2/Srk1, showing the 1141	
presence of the conserved activation loop Cys residue; C358 in Pka1 and C324 in Srk1. (B-C) 1142	
Analysis of exponentially growing wild-type; WT(JY333) or Δpka1 (JX384) S. pombe 1143	
expressing pk-tagged wild type Pka1, Pka1C358S or Pka1C358A compared with vector 1144	
control(Rep41pkc) suggests that (B) C358 is important for the kinase activity of Pka1. Pka1-1145	
dependent phosphorylated substrates, detected using Phospho	 PKA	 substrate	 (RRXS*/T*) 1146	
antibodies in samples from wild-type (WT) but not Δpka1 cells, are indicated by arrows on 1147	
the upper panel. Anti-Pk antibodies were used to show that wild type Pka1-Pk, Pka1C358S –Pk 1148	
and Pka1C358A-Pk proteins are expressed at similar levels in these samples. Tubulin antibodies 1149	
were used to confirm similar loading. *indicates a band that is increased in cells lacking Pka1. 1150	
(C) C358 in Pka1 is dispensable for growth under control conditions but required for the 1151	
growth of S. pombe on plates containing 1M KCl.. (D-E) Analysis of exponentially growing 1152	
wild-type S. pombe (AD38) expressing wild-type Myc-tagged Srk1, Srk1C324S or Srk1C324A 1153	
compared with vector control (Rep41HM) reveals (D) that mutants in which cysteine 324 is 1154	
substituted are less effective at delaying mitotic entry (increasing cell length) than wild-type 1155	
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Srk1. The graph shows the cell length of >94 newly divided cells (such as those indicated by 1156	
arrowheads in images). (E) wild-type myc—tagged Srk1C324S and Srk1C324A Srk1 proteins are 1157	
expressed at similar levels, relative to a tubulin loading control. (F) Analysis of Cdc25-GFP-1158	
expressing cells (KGY4337) co-expressing wild-type Srk1, Srk1C324S or Srk1C324A, compared 1159	
with vector control (Rep41HM) using fluorescence microscopy. In the right panel, cells were 1160	
stained with DAPI to visualise DNA (blue), confirming that wild-type Srk1 promotes the 1161	
nuclear exclusion of CDC25GFP much more effectively than Srk1C324S or Srk1C324A.  1162	
 1163	
Figure 7. Analysis of redox regulation in human MAPKAP-K2, PLK1 and PLK4  1164	
(A) 10 nM GST-MAPKAP-K2 was incubated on ice for 30 mins in the presence or absence 1165	
of 5 mM H2O2. Reactions were then initiated with the addition 1 mM ATP and substrate 1166	
peptide in the presence (where indicated) of 10 mM DTT.  (B) Immunoprecipitations of N-1167	
terminal Myc-tagged WT and C244A MAPKAP-K2 from HEK 293T cells from two 1168	
independent transfection experiments. Western blots of lysates were probed for transient 1169	
overexpression of Myc-MAPKAP-K2 using an antibody for Myc-tagged proteins (top panel). 1170	
Purified MAPKAP-K2 was detected following 3C protease dependent elution by western 1171	
blotting followed by Ponceau staining (bottom panel). EGFP transfections were used as a 1172	
negative control (C) The activity of immunoprecipitated WT and C244A MAPKAP-K2 was 1173	
measured in the presence of 1 mM DTT (red), 1 mM diamide (blue), or buffer control (black), 1174	
with 1 mM ATP. MAPKAP-K2-dependent phosphorylation of fluorescent substrate peptide 1175	
was monitored in real time. The data shown is the average and SD of two independent 1176	
immunoprecipitation experiments each assayed in duplicate. Equal volumes of eluted protein 1177	
were used in each assay for WT and mutant proteins. (D) Redox regulation of PLK1catalytic 1178	
domain. GST-PLK1 (160 nM) was assayed as for PKA, in the presence of the indicated 1179	
concentration of H2O2 or DTT and activity was normalized relative to buffer control. (E) 1180	
Reversible redox regulation of PLK1. (F) Immunoprecipitations of N-terminal Myc-tagged 1181	
WT and C212A PLK1 from HEK 293T cells from two independent transfections. 1182	
Overexpressed Myc-PLK1 was detected in lysates using anti-Myc antibody (top panl) and 1183	
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purified PLK1 was confirmed using anti-PLK1 antibody (bottom panel). EGFP control data 1184	
also shown. (G) The activity of immunoprecipitated WT and C212A PLK1 was measured in 1185	
the presence of 1 mM DTT (red), 1 mM diamide (blue), or 100 µM of the PLK-specific 1186	
inhibitor BI 2536 (black) with 1 mM ATP. Activity was calculated relative to a control 1187	
(buffer only) after 2 h assay time. (H) Redox regulation of WT and C172A His-PLK4. His-1188	
PLK4 (4 µM) was assayed with H2O2 or DTT and activity was normalized relative to control. 1189	
(I) Reversible redox regulation of WT PLK4.  1190	
 1191	
Figure 8. Redox response of an engineered Ser/Thr kinase:  A DFG+2 Cys residue 1192	
generates an obligate DTT requirement for catalytic activity in Aurora A. 1193	
(A) Activation segment amino acid conservation in 2,285 Aurora kinase-like AGC family 1194	
members from diverse eukaryotic kinomes. Human Aurora A sequence annotation is used to 1195	
highlight Asp274 and Glu299, which encompass the activation segment. The T-loop residue 1196	
(Thr288) is highlighted. The height of the letters indicates the relative frequency of the amino 1197	
acid at each position. (B) The activity of Aurora A and DFG +2 point mutants, S278A and 1198	
S278C (25 nM) was measured in the presence (red) or absence (black) of 10 mM DTT. 1199	
Aurora A-dependent phosphorylation of fluorescent substrate peptide was monitored in real 1200	
time. (C) Comparison of WT (red bars), S278A (green bars) and S278C (black bars) Aurora 1201	
A catalytic activity (pmoles of phosphate incorporated into substrate per minute) at 10 min 1202	
time point. (D) Direct comparison of Aurora A DFG+2 mutants. S278A (green bars) and 1203	
S278C (black bars). 25 nM of each enzyme was assayed with the indicated concentration of 1204	
H2O2 or DTT. Data is presented as rate of peptide phosphorylation (pmol phosphate/min). (E) 1205	
Reversible redox regulation of Aurora A DFG+2 mutants. Aurora A (25 nM) activity was 1206	
monitored in real time in the presence (blue) or absence (black) of 2 mM H2O2. After 30 1207	
mins, reactions were supplemented (where indicated) with 5 mM DTT (red). Aurora A 1208	
dependent phosphorylation of the fluorescent peptide substrate was monitored using assay 1209	
conditions described in (B). (F) Disulfide bonding of a S278C mutant to C290 in the active 1210	
site of Aurora kinase A. MS/MS spectrum of the triply charged peptide ion of m/z 593.9391, 1211	
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fragmented using HCD. Peptide sequence is displayed with the annotated HCD product ions 1212	
labelled, including the position of the Cys1 (278) – Cys13 (290) disulfide bond. HCD resulted 1213	
in peptide backbone fragmentation and cleavage of the disulfide bond (producing 1214	
dehydroalanine or disulfohydryl cysteine with mass shifts of -33.987 and +31.971 amu 1215	
respectively[153]. a/b ions (red), y ions (blue), internal ions (green) and precursor derived 1216	
product ions (orange) are annotated, including charge state and neutral losses. MS1 mass is 1217	
equivalent to a singly phosphorylated peptide, however the specific site(s) of phosphorylation 1218	
could not be localised in the spectrum. (G) 7 nM PDK1 phosphorylated His-S473D AKT was 1219	
incubated on ice for 30 mins in the presence or absence of 5 mM H2O2. Reactions were 1220	
initiated with 1 mM ATP and substrate peptide in the presence (where indicated) of 10 mM 1221	
DTT.  (H) Reversible redox regulation of MELK. Peroxide-mediated inhibition of MELK 1222	
activity is reversed by addition of DTT. (I) Redox regulation of MELK and mutants. WT and 1223	
activation loop Cys mutants (50 nM) were assayed with H2O2 (left) or DTT (right), and 1224	
activities normalized relative to controls. In these assays, kinases were incubated on ice for 30 1225	
mins in the presence or absence of 5 mM H2O2. Reactions were then initiated with the 1226	
addition of 1 mM Mg-ATP and substrate peptide in the presence or absence of 10 mM DTT. 1227	
In all experiments, kinase-optimised fluorescent peptide substrates were used (see Table 3). 1228	
Figure 9. Reversible oxidation of a conserved Cys residue regulates the activity of 1229	
multiple Ser/Thr kinases. 1230	
A panel of AGC and CAMK-related kinases were probed for reversible oxidation-dependent 1231	
inhibition using real time phosphorylation of kinase specific peptide substrates (Table 3). In 1232	
all assays, kinases were incubated on ice for 30 mins in the presence or absence of 5 mM 1233	
H2O2. Reactions were then initiated with the addition 1 mM ATP and substrate peptide in the 1234	
presence (where indicated) of 10 mM DTT. Kinases were assayed at the following final 1235	
concentrations: (A) 15 nM MAPKAP-K3, (B) 24 ng His-AMPK a1 + b2 + γ1, (C) 0.5 µM 1236	
MBP-SIK1, (D) 2 nM GST-SIK2, (E) 2 nM GST-SIK3, (F) 0.7 µM CaMK1A, (G) 60 nM 1237	
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GST-CaMK1D, (H) 0.6 µMCaMK2G and (I) 0.6 µM CaMK2D. All assays including CaMKs 1238	






Table 1. Human protein kinases containing the Aurora A Cys 290 equivalent in the 1244	
Activation Segment. Human kinases (Uniprot ID) and sequence of the activation 1245	
segment. 1246	
Protein Kinase Gene Name (UniProt ID) Activation Segment Sequence (Cys) 
TSSK1 (Q9BXA7) DFSFSKRCLRDDSGRMALSKTFCGSPAYAAPE 
TSSK2 (Q96PF2) DFGFSKRCLRDSNGRIILSKTFCGSAAYAAPE 
TSSK3 (Q96PN8) DFGFAKVLPKSHRELSQTFCGSTAYAAPE 
TSSK4 (Q6SA08) DFGFAKMVPSNQPVGCSPSYRQVNCFSHLSQTYCGSFAYACPE 
TSSK6 (Q9BXA6) DFGFGRQAHGYPDLSTTYCGSAAYASPE 
KS6B1 (P23443) DFGLCKESIHDGTVTHTFCGTIEYMAPE 
KS6B2 (Q9UBS0) DFGLCKESIHEGAVTHTFCGTIEYMAPE 
KS6A1 (Q15418) #1 DFGFAKQLRAENGLLMTPCYTANFVAPE 
KS6A2 (Q15349) #1 
 
DFGFAKQLRAGNGLLMTPCYTANFVAPE 
KS6A3 (P51812) #1 DFGFAKQLRAENGLLMTPCYTANFVAPE 
KS6A6 (Q9UK32) #1 DFGFAKQLRGENGLLLTPCYTANFVAPE 
KS6A1 (Q15418) #2 DFGLSKEAIDHEKKAYSFCGTVEYMAPE 
KS6A2 (Q15349) #2 DFGLSKEAIDHDKRAYSFCGTIEYMAPE 
KS6A3 (P51812) #2 DFGLSKESIDHEKKAYSFCGTVEYMAPE 
KS6A4 (O75676) DFGLSKEFLTEEKERTFSFCGTIEYMAPE 
KS6A5 (O75582) DFGLSKEFVADETERAYSFCGTIEYMAPD 
KS6A6 (Q9UK32) #2 DFGLSKESVDQEKKAYSFCGTVEYMAPE 
AKT1 (P31749) DFGLCKEGIKDGATMKTFCGTPEYLAPE 
AKT2 (P31751) DFGLCKEGISDGATMKTFCGTPEYLAPE 
AKT3 (Q9Y243) DFGLCKEGITDAATMKTFCGTPEYLAPE 
PLK1 (P53350) DFGLATKVEYDGERKKTLCGTPNYIAPE 
PLK2 (Q9NYY3) DFGLAARLEPLEHRRRTICGTPNYLSPE 
PLK3 (Q9H4B4) DFGLAARLEPPEQRKKTICGTPNYVAPE 




MAST2 (Q6P0Q8) DFGLSKIGLMSLTTNLYEGHIEKDAREFLDKQVCGTPEYIAPE 
MAST3 (O60307) DFGLSKIGLMSMATNLYEGHIEKDAREFIDKQVCGTPEYIAPE 
MAST4 (O15021) DFGLSKVGLMSMTTNLYEGHIEKDAREFLDKQVCGTPEYIAPE 
KAPCA/PKAa (P17612) DFGFAKRVKGRTWTLCGTPEYLAPE 
KAPCB/PKAb (P22694) DFGFAKRVKGRTWTLCGTPEYLAPE 
KAPCG/PKAg (P22612) DFGFAKRVKGRTWTLCGTPEYLAPE 
PRKX (P51817) DFGFAKKLVDRTWTLCGTPEYLAPE 
PRKY (O43930) DFGFAKKLVDRTWTLCGTPEYLAPE 
KGP1/PKG1 (Q13976) DFGFAKKIGFGKKTWTFCGTPEYVAPE 
KGP2/PKG2 (Q13237) DFGFAKKIGSGQKTWTFCGTPEYVAPE 
PKN1 (Q13976) DFGLCKEGMGYGDRTSTFCGTPEFLAPE 
PKN2 (Q13237) DFGLCKEGMGYGDRTSTFCGTPEFLAPE 
PKN3 (Q6P5Z2) DFGLCKEGIGFGDRTSTFCGTPEFLAPE 
JAK1 (P23458) DPGIPITVLSRQECIERIPWIAPE 
SGK494 (Q96LW2) DFGLSRHVPQGAQAYTICGTLQYMAPE 
SGK1 (O00141) DFGLCKENIEHNSTTSTFCGTPEYLAPE 
SGK2 (Q9HBY8) DFGLCKEGVEPEDTTSTFCGTPEYLAPE 
SGK3 (Q96BR1) DFGLCKEGIAISDTTTTFCGTPEYLAPE 
AAPK1 (Q13131) DFGLSNMMSDGEFLRTSCGSPNYAAPE 
AAPK2 (P54646) DFGLSNMMSDGEFLRTSCGSPNYAAPE 
BRSK1 (Q8TDC3) DFGMASLQVGDSLLETSCGSPHYACPE 
BRSK2 (Q8IWQ3) DFGMASLQVGDSLLETSCGSPHYACPE 
KPCA/PKCa (P17252) DFGMCKEHMMDGVTTRTFCGTPDYIAPE 
KPCB/PKCb (P05771) DFGMCKENIWDGVTTKTFCGTPDYIAPE 
KPCD/PKCd (Q05655) DFGMCKENIFGESRASTFCGTPDYIAPE 
KPCE/PKCe (Q02156) DFGMCKEGILNGVTTTTFCGTPDYIAPE 
KPCG/PKCg (P05129) DFGMCKENVFPGTTTRTFCGTPDYIAPE 
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KPCI/PKCi (P41743) DYGMCKEGLRPGDTTSTFCGTPNYIAPE 
KPCL/ PKCl  (P24723) DFGMCKEGICNGVTTATFCGTPDYIAPE 
KPCT/PKCt  (Q04759) DFGMCKENMLGDAKTNTFCGTPDYIAPE 
KPCZ/ PKCz  (Q05513) DYGMCKEGLGPGDTTSTFCGTPNYIAPE 
AURKA (O14965) DFGWSVHAPSSRRTTLCGTLDYLPPE 
AURKB (Q96GD4) DFGWSVHAPSLRRKTMCGTLDYLPPE 
AURKC (Q9UQB9) DFGWSVHTPSLRRKTMCGTLDYLPPE 
CHK1 (O14757) DFGLATVFRYNNRERLLNKMCGTLPYVAPE 
CHK2 (O96017) DFGHSKILGETSLMRTLCGTPTYLAPE 
STK35 (Q8TDR2) DFGLSKVCAGLAPRGKEGNQDNKNVNVNKYWLSSACGSDFYMAPE 
PDK1L (Q8N165) DFGLSKVCSASGQNPEEPVSVNKCFLSTACGTDFYMAPE 
HUNK (P57058) DFGLSNCAGILGYSDPFSTQCGSPAYAAPE 
MARK1 (Q9P0L2) DFGFSNEFTVGNKLDTFCGSPPYAAPE 
MARK2 (Q7KZI7) DFGFSNEFTFGNKLDTFCGSPPYAAPE 
MARK3 (P27448) DFGFSNEFTVGGKLDTFCGSPPYAAPE 
MARK4 (Q96L34) DFGFSNEFTLGSKLDTFCGSPPYAAPE 
SGK196/POMK (Q9H5K3) DLDALPLVNHSSGMLVKCGHRELHGDFVAPE 
ULK1 (O75385) DFGFARYLQSNMMAATLCGSPMYMAPE 
ULK2 (Q8IYT8) DFGFARYLHSNMMAATLCGSPMYMAPE 
BUB1 (O43683) DLGQSIDMKLFPKGTIFTAKCETSGFQCVE 
MELK (Q14680) DFGLCAKPKGNKDYHLQTCCGSLAYAAPE 
NIM1 (Q8IY84) DFGFSTVSKKGEMLNTFCGSPPYAAPE 
NUAK1 (O60285) DFGLSNLYQKDKFLQTFCGSPLYASPE 
NUAK2 (Q9H093) DFGLSNLYHQGKFLQTFCGSPLYASPE 
SIK1 (P57059) DFGFGNFYKSGEPLSTWCGSPPYAAPE 
SIK2 (Q9H0K1) DFGFGNFFKSGELLATWCGSPPYAAPE 
SIK3 (Q9Y2K2) DFGFSNLFTPGQLLKTWCGSPPYAAPE 





SNRK (Q9NRH2) DFGFSNKFQPGKKLTTSCGSLAYSAPE 
KCC1A/CAMK1A (Q14012) DFGLSKMEDPGSVLSTACGTPGYVAPE 
KCC1B/CAMK1B (Q6P2M8) DFGLSKIQAGNMLGTACGTPGYVAPE 
KCC1D/CAMK1D (Q8IU85) DFGLSKMEGKGDVMSTACGTPGYVAPE 
KCC1G/CAMK1G (Q96NX5) DFGLSKMEQNGIMSTACGTPGYVAPE 
KCC4/CAMK4 (Q16566) DFGLSKIVEHQVLMKTVCGTPGYCAPE 
CAMKV (Q8NCB2) DFHLAKLENGLIKEPCGTPEYLAPE 
DCLK1 (O15075) DFGLATIVDGPLYTVCGTPTYVAPE 
DCLK2 (Q8N568) DFGLATVVEGPLYTVCGTPTYVAPE 
DCLK3 (Q9C098) DFGLAKHVVRPIFTVCGTPTYVAPE 
MKNK1/MNK1 (Q9BUB5) DFDLGSGMKLNNSCTPITTPELTTPCGSAEYMAPE 
MKNK2/MNK2 (Q9HBH9) DFDLGSGIKLNGDCSPISTPELLTPCGSAEYMAPE 
PASK (Q96RG2) DFGSAAYLERGKLFYTFCGTIEYCAPE 
PHKG1 (Q16816) DFGFSCQLEPGERLREVCGTPSYLAPE 
PHKG2 (P15735) DFGFSCHLEPGEKLRELCGTPGYLAPE 
KPSH1/PSKH1 (P11801) DFGLASARKKGDDCLMKTTCGTPEYIAPE 
KPSH2/PSKH2 (Q96QS6) DFGLAYSGKKSGDWTMKTLCGTPEYIAPE 
STK33 (Q9BYT3) DFGLAVKKQSRSEAMLQATCGTPIYMAPE 
RSK KS6A4 (O75676) DFGFARLRPQSPGVPMQTPCFTLQYAAPE 
RSK KS6A5 (O75582) DFGFARLKPPDNQPLKTPCFTLHYAAPE 
MAPKAP-K2 (P49137) DFGFAKETTSHNSLTTPCYTPYYVAPE 
MAPKAP-K3 (Q16644) DFGFAKETTQNALQTPCYTPYYVAPE 
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Table 2. Positional evaluation of all human kinases that contain Cys residues in the 1250	
Activation Segment. The location of the Cys residue relative to the end of the DFG motif 1251	
is shown and includes the total number of kinases at each position and the commonly used 1252	
names of each kinase.  1253	
Cys Position Number in human kinome Human kinase/pseudokinase name 
DFG + 1 5 MAP3K4/MEKK4, MAP3K8/COT, MOS, 
PINK1, HSER/GUCY2C 
DFG +2 43 p70S6K, p70S6Kb, PKCa, PKCb,  
PKCg,  PKCd,  PKCe, PKCi, PKCl,  
PKCt, PKCz,  PKN1, PKN2, PKN3, 
AKT1, AKT2, AKT3, SGK1, SGK2, 
SGK3, MRCKa, MRCKb, DMPK1, 
DMPK2, ROCK1, ROCK2, IRE1, IRE2, 
LATS1, LATS2, MELK, MOK, NDR1, 
NDR2, PAK1, PAK2, PAK3, PAK4, 
PAK5, PAK6, PINK1, SGK496, SCYL2 
DFG +3 15 BARK1, BARK2,PHKg1, PHKg2, 
DYRK1A, DYRK1B, DYRK2, DYRK3, 
DYRK4, SRPK1, SPRK2, MSSK1, 
TAK1, SCYL3, TRIB3 





TSSK1, TSSK2, IRAK2, LRRK2 
DFG +6 2 MPSK1/STK16, LRRK2 
DFG +7 1 JNK2 
DFG +8 4 MNK1, MNK2, GCN2, SGK069/SBK 
DFG +9 5 LATS1, LATS2, PSKH1, RYK, 
DRAK2/STK17B 
DFG +10 4 CDK5, MAP3K5/ASK1, MAP3K6/ASK2, 
MAP3K7/TAK1 
DFG +11 12 NRBP1, RSKL1, RSKL2, LKB1, HIPK1, 
HIPK2, HIPK3, ILK, FGR/SRC2, IKKa, 
IKKb, IRE2 




3 SPEG, VRK1, PBK/TOPK 
DFG +14/ 
T-LOOP +1 




99 Described in detail in Table 1 
DFG +16/  
T-LOOP +3 
3 GSK3a, GSK3b, MPSK1 
DFG + 17/ 
T-LOOP +4 
8 EPHB6, MAP2K3/MKK3, 
MAP2K4/MKK4, MAP2K6/MKK6, 
MAP2K7/MKK7, TRIB1, TRIB2, TRIB3 
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DFG +18 2 RIOK1, HRI/eIF2aK 
DFG + 19 7 KSR1, KSR2, NEK8, OSR1, PINK1, 
PIK3R4, STLK3 
DFG +20 1 Haspin 
DFG + 21 
(APE-1) 





Table 3. Protein kinase enzymes and substrates. Sequence of recombinant protein 1256	
kinases and peptide substrates employed for assay of purified human protein kinases. 1257	
Sources of enzymes (insect cell or bacteria) are included. 5FAM=5-carboxyfluorescein 1258	
Purified recombinant Protein Kinase Peptide substrate sequence 
MBP-SIK1 (2-783) Sf21 cells (DU40321) 5FAM-ALNRTSSDSALHRRR-CONH2 
GST-SIK2 (2-926) Sf21 cells (DU16623), 
GST-SIK3 (2-1369) Sf21 cells (DU 16624) 5FAM-KKVSRSGLYRSPSMPENLNRPR-CONH2 
His-AMPK α1 (11-559) + β2 (1-272) + γ1 (1-
331) Sf21 cells (DU32489) 5FAM-AMARAASAAALARRR-CONH2 
Full length human myc-3C-PLK1 or GST-
PLK1 (1–369) E. coli 5FAM-AEEISDELMEFSLKDQEA-CONH2 
His-PLK4 (1-269) E. coli 5FAM-FLAKSFGSPNRAYKK-CONH2 
His-ABL (46-515) E. coli 5FAM-EAIYAAPFAKKK-CONH2 
(GST-cleaved) PHK (1-297) E. coli (DU733) 5FAM-KRKQISVRGL-CONH2 
His-AKT (118-470) Sf21 cells 5FAM-GRPRTSSFAEG-CONH2 
(GST-cleaved) CAMK1A (2-369) E. coli 
(DU1148), GST-CAMK1D (1-385) E. coli 
(DU37123) 
5FAM-KKLNRTLSVA-CONH2 
(GST- cleaved) CAMK2D (1-478) E. coli 
(DU33795), (GST- cleaved) GST-CAMK2G 
(1-527) E. coli (DU51376) 
5FAM-KKLNRTLSVA-CONH2 
Full length human myc-3C-MAPKAP-K2, 
GST-MAPKAP-K2 (46-400) E. coli 
(DU1714), (GST-cleaved) MAPKAP-K3 (2-
382) E. coli (DU929), 
5FAM-KKLNRTLSVA-CONH2 
His-Aurora A (Full length, 1-403) E. coli, His-
PKA (Full length,1-351) E. coli, His-PKG1-1 
(Full length, 1-671) Sf21 (DU26285), His-
PKG1-2 (Full length, 1-686) Sf21 (DU26299) 
5FAM-LRRASLG-CONH2 
GST-MELK (1-340) E. coli 5FAM-AMARAASAAALARRR-CONH2 




Table 4. Yeast strains described in this study 1261	
Strain Genotype Source or 
reference 




KGY4337 h− cdc25-GFP:KanR ura4-D18 ade6-M210 leu1-32 [164] 
JX333 h- ade6-M216 leu1-32 
 
[165] 
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SUPPLEMENTARY FIGURE LEGENDS: 1288	
Supplementary Figure 1. Chemical routes for Cys redox modifications in proteins, and 1289	
their detection with commercial reagents. A redox flow-chart is presented. Note the DTT 1290	
reversibility of the sulfenic Cys and disulfide species and detection of glutathionylated and 1291	
dimedone-conjugated sulfenylated cysteines using commercial antibodies. 1292	
 1293	
Supplementary Figure 2. Analysis of Aurora A purified in the presence of DTT. 1294	
(A) Recombinant Aurora A (0.5 µg each) purified in the presence or absence of DTT and 1295	
resolved by SDS-PAGE and visualised by Coomassie blue staining (top panel). 1296	
Phosphorylation (pThr 288) of each protein (20 ng) was also analysed by immunoblotting 1297	
(bottom panel). (B) Dose response curves for H2O2 incubated for 16 h (left panel) or 2 h (right 1298	
panel) with 5 µM recombinant Aurora A in the presence of 1 mM ATP and 2.5 mM MgCl2. 1299	
Aurora A was then diluted to 50 nM and the enzymes activity was assessed by monitoring 1300	
phosphorylation of a fluorescent peptide substrate, and normalized to controls as previously 1301	
described. Half-maximal inhibitory concentration (IC50) of H2O2 under these conditions was 1302	
calculated to be <10 µM.(C) Dose response curves for the reducing reagent DTT (red) and the 1303	
oxidizing agents H2O2 (blue) and diamide (green) with 6 nM recombinant Aurora A purified 1304	
in the presence of DTT. Aurora A activity was assessed by monitoring phosphorylation of a 1305	
fluorescent peptide substrate using 1 mM ATP, and normalized to control experiments 1306	
containing buffer alone after 30 min assay time. (D) Oxidative-inhibition of Aurora A 1307	
purified in the presence of DTT is reversible. Assay conditions are as described in Fig. 1C.	1308	
 1309	
Supplementary Figure 3. Biochemical analysis of Aurora A oxidation. 1310	
(A) Aurora A stability is unaffected by redox state. Thermal denaturation profiles of 1311	
recombinant Aurora A (5 µM) in the presence of 1 mM of the indicated redox-reagent. 1312	
Representative unfolding profiles of two independent experiments shown. (B) KM[ATP] 1313	
determination for Aurora A (12.5 nM) in the presence of H2O2. Kinetic analysis of Aurora A-1314	
catalysed peptide phosphorylation (pmol phosphate/min) with increasing concentrations of 1315	
ATP was performed with the indicated concentrations of H2O2. KM[ATP] values (± standard 1316	
deviation) were calculated from two independent experiments using GraphPad Prism 1317	
software. (C) Analysis of thermal shifts induced by 1 mM ATP and 100 µM MLN8237 in the 1318	
presence of 1 mM of the indicated redox-reagent. Means of two independent experiments are 1319	
shown. 1320	
 1321	
Supplementary Figure 4. Analysis of Aurora A and a redox-resistant C290A mutant. 1322	
 51 
(A) Purified WT and C290A Aurora A (0.5 µg each) resolved by SDS-PAGE and visualised 1323	
by Coomassie blue staining (top panel) and immunoblot (50 ng protein) using antibodies with 1324	
specificity for Aurora A (middle panel) and site specific autophosphorylation at Thr 288 1325	
(bottom panel). (B) Thermal denaturation profiles of recombinant Aurora A proteins 5 µM. 1326	
Representative unfolding profiles from two independent experiments are shown. (C) Thermal 1327	
shifts induced by 1 mM ATP and 100 µM MLN8237. (D) Calculation of KM[ATP] values for 1328	
WT (red) and C290A Aurora A (blue). ATP concentrations were varied in the presence of a 1329	
fixed amount (6 nM) of Aurora A protein. The rate of peptide substrate phosphorylation 1330	
(pmol phosphate/min) was calculated from two independent experiments using GraphPad 1331	
Prism software. (E) Immunoblot of an in vitro kinase assay using recombinant GST-TACC3 1332	
as a substrate for C290A Aurora A. Aurora A (50 ng) was incubated with the indicated 1333	
concentrations of H2O2 and DTT or 0.1 mM of the Aurora A-specific inhibitor MLN8237 for 1334	
30 mins at 20 °C. The kinase assay was initiated following the addition of GST-TACC3 (1 1335	
µg) and C290A Aurora A-dependent phosphorylation of TACC3 (pSer558, top panel) was 1336	
detected after 15 mins. 0.5 mM ATP and 5 mM MgCl2 were included in the reaction. 1337	
Reactions were terminated by the addition of SDS loading buffer. Equal loading of TACC3 1338	
substrate was confirmed with anti-TACC3 antibody (second panel from top). Also shown is 1339	
total (second panel from bottom) and phosphorylated C290A Aurora A (pThr 288, bottom 1340	
panel). 1341	
 1342	
Supplementary Figure 5. Analysis of C290S and C290D mutants. 1343	
(A) Purified WT, C290A, C290S, C290D and kinase-dead (D274N) Aurora A (50 ng each 1344	
protein) were resolved by SDS-PAGE immunoblotted using antibodies with specificity for 1345	
Aurora A (top panel) and site specific autophosphorylation at Thr 288 (bottom panel). (B) 1346	
Thermal denaturation profiles of recombinant Aurora A proteins (5 µM). Representative 1347	
unfolding profiles from two independent experiments are shown. (C) Thermal shifts induced 1348	
by 1 mM Mg-ATP or 100 µM MLN8237. (D) Real-time kinase assays performed using a 1349	
fluorescent peptide substrate performed with the indicated amounts of WT, C290S and 1350	
C290D Aurora A proteins.  1351	
 1352	
Supplementary Figure 6. WT and C290A Aurora A both bind to TPX2. 1353	
(A) Interaction of WT and C290A His-Aurora A with GST-TPX2 under oxidizing and 1354	
reducing conditions. 5 µM WT Aurora A was incubated with the indicated concentrations of 1355	
H2O2 or DTT for 5 mins at 20 °C and pulled down with GST-TPX2 glutathione beads (~1 µg 1356	
GST-TPX2 per 10 µl bead volume). Protein was eluted with 10 mM GSH. Pull down assays 1357	
with C290A Aurora A also shown. Control experiments used GST as a bait protein. (B) 1358	
Redox regulation of TPX2-bound WT and C290A Aurora A. WT (red) and C290A (blue) 1359	
 52 
Aurora A proteins were incubated with TPX2 and then assayed in the presence of 1 mM DTT 1360	
or 10 mM H2O2. Activity was calculated relative to a control containing buffer only after 5 1361	
mins assay time. In all assays described here, Aurora A proteins were incubated with TPX2 1362	
for 10 mins at 20 °C before the addition of redox reagent or ATP. The concentration of TPX2 1363	
in the final reaction mixture was fixed at 100 nM. (C) The activity of WT (red) and C290A 1364	
(blue) Aurora A (6 nM, assayed with 1 mM ATP) was evaluated using peptide substrate in 1365	
the presence or absence of GST-TPX2. GST at an equimolar concentration to TPX2 included 1366	
as a control. (D) Activation of C290S (circles) but not C290D (squares) Aurora A (2.5 µM, 1367	
with 1 mM ATP) in the presence or absence of TPX2 (20 µM) or DTT (10 mM). (E) 1368	
Immunoblot of an in vitro kinase assay using recombinant GST-TACC3 (1 µg) as a substrate 1369	
for WT, C290A and C290S Aurora A. Aurora A (100 ng) was incubated with a peptide 1370	
derived from TPX2 (10 µM) and Aurora A-dependent phosphorylation of TACC3 (pSer558, 1371	
top panel) was detected after 30 mins. 0.5 mM ATP and 5 mM MgCl2 were included in the 1372	
reaction. Reactions were terminated by the addition of SDS loading buffer. Equal loading of 1373	
TACC3 substrate was confirmed with anti-TACC3 antibody (second panel from top). Also 1374	
shown is total (second panel from bottom) and phosphorylated Aurora A (pThr 288, bottom 1375	
panel). 1376	
 1377	
Supplementary Figure 7. Reversible glutathionylation of Aurora A and AKT. 1378	
(A) Immunoblot demonstrating reversible glutathionylation of Aurora A. 1 µg of recombinant 1379	
Aurora A protein was incubated in the presence or absence of 10 mM GSSG for 30 mins at 1380	
20°C. SDS-PAGE was performed under reducing and non-reducing conditions. Western blots 1381	
were probed with an antibody with specificity towards glutathione-conjugated proteins. Equal 1382	
loading of protein was confirmed using an antibody for Aurora A. PKA (1 µg) was also 1383	
included as a positive control. (B) Inhibition of Aurora A by H2O2 is relieved by DTT but not 1384	
GSH. Aurora A (12.5 nM) activity was assayed in the presence or absence of 1 mM H2O2 for 1385	
25 mins and the reactions were then supplemented (where indicated) with 2 mM GSH, 1386	
followed by 2 mM DTT after 50 mins. Aurora A-dependent phosphorylation of the 1387	
fluorescent peptide substrate was initiated by the addition of 1 mM ATP. (C) Aurora A (40 1388	
µM) was incubated in the presence or absence of 125 µM diamide or diamide with 100 µM 1389	
GSH for 20 mins at 20 °C. Following this, reactions were supplemented with buffer control, 1390	
500 µM GSH and 0.16 mg/ml glutaredoxin-1 (GRX), or GSH and GRX in isolation for a 1391	
further 20 mins. Reactions were then sampled for western blotting analysis (upper panel) or 1392	
assayed using in vitro kinase assay (final Aurora A concentration was 200 nM, bottom panel). 1393	
Data shown is mean and SD of two independent experiments. (D) AKT is potently activated 1394	
by GSH. Activity of PDK1 phosphorylated S473D AKT (7 nM) was measured in the 1395	
presence or absence of 2 mM GSH and 1 mM ATP. 1396	
 53 
 1397	
Supplementary Figure 8. Taxonomic analysis of conserved Cys residues within the 1398	
activation segment of ePKs. 1399	
 1400	
(A) The distribution of Cys residues, and co-varying amino acids at all positions within the 1401	
activation segment, located between the DFG and APE residues, are displayed using 1402	
WebLogos. The percentage of ePKs containing the indicated Cys residues is indicated on the 1403	
right. (B) Kinome group distribution of all ePKs containing a Cys 290 equivalent. The total 1404	
number of kinases identified within each group is indicated. (C) Taxonomic distribution of T 1405	
loop +2 Cys-containing sequences in all ePKs (D) Aurora kinases, (E) PKA and (F) PLK sub-1406	
families. Taxonomic groups are coloured as indicated and the total number of sequences 1407	
identififed in each category are indicated within the pie chart.  1408	
 1409	
Supplementary Figure 9. Biochemical analysis of Cys-containing protein kinases. 1410	
 1411	
(A) Purified WT and Cys-Ala mutants kinases (0.5 µg each) resolved by SDS-PAGE and 1412	
visualised by Coomassibe blue staining. (B) Detection of reactive cysteine oxidation in WT 1413	
and Cys-Ala recombinant MELK proteins with an antibody with specificity towards cysteine 1414	
sulfenic acids that have been derivatised by dimedone (SOH-MELK). GST-MELK (0.5 µg) 1415	
was incubated in the presence of absence of 1 mM H2O2 for 10 min and then exposed to 1 1416	
mM dimedone for a further 20 mins (all incubations performed at 20°C). Total GST-MELK 1417	
loading was visualised using ponceau staining (bottom panel). 1418	
 1419	
Supplementary Figure 10. Thermal profiling and immunoblotting-based redox analysis 1420	
of Aurora A ‘DFG +2’ kinase mutants. 1421	
 1422	
(A) Bacterially expressed WT, S278A or S279C Aurora A (2 µg each) were purified in the 1423	
absence of DTT, resolved by SDS-PAGE and visualised by Coomassie blue staining. (B) 1424	
Thermal denaturation profiles of purified Aurora A proteins (5 µM). Representative unfolding 1425	
profiles from three independent experiments are shown. Calculated Tm values are shown for 1426	
each protein. (C) Change in Tm values (DTm) induced by DTT or ATP/Mg incubation were 1427	
determined from thermal melt curves. (D) DTT-dependent changes in the electrophoretic 1428	
mobility of WT, S278A and S278C Aurora A were investigated in the presence and absence 1429	
of H2O2. Aurora A (50 ng) was incubated with the indicated concentration of H2O2 for 10 1430	
mins at 20°C and analysed after non-reducing (-DTT) or reducing (+DTT) SDS-PAGE. Total 1431	







Supplementary Figure 11. Kinases possessing a T-loop +2 Cys residue that are 1438	
insensitive to redox-dependent regulation.   1439	
 1440	
A cohort of kinases with suspected redox sensitivity based on the presence of an analogous 1441	
activation loop-located Cys residue were probed for reversible oxidation-dependent inhibition 1442	
using real time phosphorylation of kinase specific peptide substrates (see Table 2). Assay 1443	
conditions were as for Fig. 7 and the following concentrations of kinases were used: (A) 4 nM 1444	
PHK, (B, C) 25 nM His-PKG1-1, and (D,E) 80 nM His-PKG1-2. Assays (C) and (E) were 1445	
supplemented with 1 mM cGMP. 1446	
 1447	
Supplementary Figure 12. Redox analysis of model Tyr kinases and Cys mutants. 1448	
Purified ABL and EPHA3 tyrosine kinases were assayed using the specified redox-dependent 1449	
conditions described in Fig. 7 and Table 2. Final ABL or EPHA3 concentrations in the assay 1450	
were: (A) 30 nM WT His-EPHA3, (B) 5 nM ABL and 30 nM of (C) G783C, (D) G784C or 1451	
(E) G783C/G784C His-EPHA3 1452	
 1453	
 1454	
Supplementary Figure 13. Structural-models of disulphide-based mechanisms involving 1455	
activation segment Cys in Ser/Thr kinases.  1456	
(A) Formation of an intramolecular disulfide in AKT between Cys residues in the activation 1457	
segment. (B) Intermolecular disulfide between exchanged activation segments of MELK. 1458	
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